<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6963626</article-id><article-id pub-id-type="pmcid-ver">PMC6963626.1</article-id><article-id pub-id-type="pmcaid">6963626</article-id><article-id pub-id-type="pmcaiid">6963626</article-id><article-id pub-id-type="pmid">31623188</article-id><article-id pub-id-type="doi">10.3390/vaccines7040150</article-id><article-id pub-id-type="publisher-id">vaccines-07-00150</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Vilander</surname><given-names initials="AC">Allison C.</given-names></name><xref rid="c1-vaccines-07-00150" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7025-9550</contrib-id><name name-style="western"><surname>Dean</surname><given-names initials="GA">Gregg A.</given-names></name><xref rid="c1-vaccines-07-00150" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-vaccines-07-00150">Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA</aff><author-notes><corresp id="c1-vaccines-07-00150"><label>*</label>Correspondence: <email>allison.vilander@colostate.edu</email> (A.C.V.); <email>gregg.dean@colostate.edu</email> (G.A.D.); Tel.: +1-970-297-5127 (A.C.V.); +1-970-491-6144 (G.A.D.)</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>7</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">350022</issue-id><elocation-id>150</elocation-id><history><date date-type="received"><day>29</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>10</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>27</day><month>01</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-05 04:25:35.593"><day>05</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-07-00150.pdf"/><abstract><p>Lactic acid bacteria (LAB) are Gram-positive, acid-tolerant bacteria that have long been used in food fermentation and are generally recognized as safe (GRAS). LAB are a part of a normal microbiome and act as probiotics, improving the gastrointestinal microbiome and health when consumed. An increasing body of research has shown the importance of the microbiome on both mucosal immune heath and immune response to pathogens and oral vaccines. Currently, there are few approved mucosal vaccines, and most are attenuated viruses or bacteria, which necessitates cold chain, carries the risk of reversion to virulence, and can have limited efficacy in individuals with poor mucosal health. On account of these limitations, new types of mucosal vaccine vectors are necessary. There has been increasing interest and success in developing recombinant LAB as next generation mucosal vaccine vectors due to their natural acid and bile resistance, stability at room temperature, endogenous activation of innate and adaptive immune responses, and the development of molecular techniques that allow for manipulation of their genomes. To enhance the immunogenicity of these LAB vaccines, numerous adjuvant strategies have been successfully employed. Here, we review these adjuvant strategies and their mechanisms of action which include: Toll-like receptor ligands, secretion of bacterial toxins, secretion of cytokines, direct delivery to antigen presenting cells, and enterocyte targeting. The ability to increase the immune response to LAB vaccines gives them the potential to be powerful mucosal vaccine vectors against mucosal pathogens.</p></abstract><kwd-group><kwd>lactic acid bacteria</kwd><kwd>mucosal vaccine</kwd><kwd>adjuvant</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-07-00150"><title>1. Introduction</title><p>Lactic acid bacteria (LAB) are Gram-positive acid-tolerant bacteria that have long been used in food fermentation and are generally recognized as safe (GRAS). Additionally, they have been identified as probiotics, live organisms that improve health when consumed [<xref rid="B1-vaccines-07-00150" ref-type="bibr">1</xref>]. LAB are a diverse group of bacteria that includes the genera <italic toggle="yes">Lactobacillus</italic> spp., <italic toggle="yes">Lactococcus</italic> spp., and <italic toggle="yes">Streptococcus</italic> spp. The effects of LAB on mucosal health are diverse and have been most heavily studied in the gastrointestinal (GI) tract. General effects of LAB in the intestinal tract are known to include alteration of the intestinal microbiome composition, improved barrier function, niche competition with pathogens, and, germane to this review, modulation of the host immune system [<xref rid="B2-vaccines-07-00150" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-07-00150" ref-type="bibr">3</xref>].</p><p>Most pathogens enter the body at mucosal sites and protection of these barrier tissues is mediated by innate and adaptive immune responses. Mucus, peristalsis, gastric acid, bile, and antimicrobial peptides are examples of innate mucosal immune defense strategies while antigen-specific antibodies and cell-mediated responses are the workhorses of the adaptive response. Induction of both innate and adaptive mucosal immune responses is best achieved by direct immunization at the mucosa rather than through systemic routes (parenteral injection) [<xref rid="B4-vaccines-07-00150" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-07-00150" ref-type="bibr">5</xref>]. Mucosal vaccines can also induce serum antibody and systemic cell-mediated responses. Mucosal delivery is an especially attractive mechanism of vaccination due to the ease of administration and the common-mucosal immune system, which allows for induction of immune responses at one mucosal surface followed by trafficking of immune cells to other distant mucosal sites [<xref rid="B4-vaccines-07-00150" ref-type="bibr">4</xref>].</p><p>Despite the inherent benefits of mucosal vaccines, there are few available for use worldwide. Of the currently licensed human mucosal delivered vaccines, all are live attenuated or inactivated viruses or bacteria. While these vaccines are effective at stimulating a strong mucosal immune response, the use of attenuated vaccines carries the risk of reversion to virulence and they cannot be used in immunologically sensitive populations [<xref rid="B6-vaccines-07-00150" ref-type="bibr">6</xref>]. In addition, these mucosal vaccines can have varying efficacy depending on an individual&#8217;s health, nutritional status, and microbiome [<xref rid="B7-vaccines-07-00150" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-07-00150" ref-type="bibr">8</xref>]. Co-delivery of LAB with oral vaccines has shown the ability to increase the immune response in the face of low nutritional status or dysbiosis. For example, increased immune responses have been seen when probiotics are administered with oral rotavirus, polio, <italic toggle="yes">Salmonella typhi</italic>, and cholera vaccines [<xref rid="B9-vaccines-07-00150" ref-type="bibr">9</xref>].</p><p>Due to the limitations of the currently available mucosal vaccines and the benefits of probiotics on immune response to vaccination, development of LAB as mucosal vaccine vectors is attractive. LAB have several attributes as orally delivered mucosal vaccines including: Acid and bile resistance, stability at room temperature, endogenous activation of innate and adaptive immune responses, and the availability of molecular techniques for genomic modification [<xref rid="B10-vaccines-07-00150" ref-type="bibr">10</xref>]. Since the 1990s, the use of LAB as an oral vaccine platform has been explored against numerous viral and bacterial pathogens and toxins [<xref rid="B11-vaccines-07-00150" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-07-00150" ref-type="bibr">12</xref>]. These vaccines have been shown to induce serum IgG and mucosal secretory (sIgA) as well as stimulate T cell responses. In addition to developing LAB for the delivery of antigens, numerous adjuvant strategies have been explored to enhance immune responses.</p><p>Adjuvants are used in conjunction with vaccines to increase the humoral and/or cellular response to a delivered antigen. Pairing the correct antigen and adjuvant can induce faster, more robust, and longer-lived (durable) immune responses, and may decrease the amount of antigen needed to induce protection [<xref rid="B13-vaccines-07-00150" ref-type="bibr">13</xref>]. Adjuvants such as Alum, MF59, AS03, AF03, virosomes, and heat labile enterotoxin (LT) have long been used with systemic vaccines but adjuvant use has been more limited with mucosal vaccines. Only the intranasal influenza vaccine, Nasalflu, has been licensed for use with a mucosal adjuvant, <italic toggle="yes">Escherichia coli</italic> heat-labile toxin (LT), but it has since been removed from the market [<xref rid="B14-vaccines-07-00150" ref-type="bibr">14</xref>].</p><p>To realize the potential of LAB as mucosal vaccine vectors, an understanding of how to enhance the immunogenicity of these vaccines while preserving the inherent safety will be required. It is likely that despite the endogenous immune activating properties of LAB, one or multiple adjuvant strategies may be necessary to induce robust and long lasting protective immune responses. This may be especially true if the vaccine is expressing poorly immunogenic antigens or is used in sensitive populations such as individuals who are immune suppressed, nutrient compromised, have an altered microbiome, or have an increased mucosal disease burden. Here, we review the current strategies being investigated to adjuvant the immune response to mucosal delivered LAB vaccine vectors. As these studies are reviewed, it is important to recognize that the adjuvant effect on the immune response may be altered by the mucosal route of administration (intranasal, oral, or intravaginal), genus and species of LAB used as the delivery vehicle, the antigen per se, and the mechanism of antigen display (secreted, surface-display, or intracellular). Careful study and selection of each of these variables will likely be necessary to develop optimized LAB mucosal vaccines.</p></sec><sec id="sec2-vaccines-07-00150"><title>2. Lactic Acid Bacteria Mechanisms of Immune Interaction and Activation</title><p>To understand the effect that adjuvant strategies have on the immune response to a LAB mucosal vaccine, it is important to review the endogenous immune activating mechanisms possessed by LAB. A brief summary of typical LAB interactions with the mucosal immune system are depicted in <xref ref-type="fig" rid="vaccines-07-00150-f001">Figure 1</xref>a.</p><p>Of note are the characteristics that make LAB especially attractive for use as a mucosal vaccine vector. LAB can stimulate innate immune response through the Gram-positive cell wall peptidoglycan and lipotechoic acid that activate the pattern-recognition receptors: Toll-like receptor (TLR) 2, nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family, and C-type lectin receptors [<xref rid="B15-vaccines-07-00150" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-07-00150" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-07-00150" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-07-00150" ref-type="bibr">18</xref>]. Various species of LAB can also activate TLR3, TLR6, TLR9, and stimulate interferon responses [<xref rid="B19-vaccines-07-00150" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-07-00150" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-07-00150" ref-type="bibr">21</xref>]. Additionally, some LAB species can bind to intestinal mucus and the mucosal epithelium and/or microfold (M) cells resulting in mucosal colonization and increased uptake and transport into mucosal immune induction sites such as Peyer&#8217;s patches in the small intestine or tonsillar crypts. LAB can interact with antigen-presenting cells (APCs) such as dendritic cells (DC) and induce sIgA and IgG. The mechanism of DC activation and the resulting immune responses are highly dependent on the LAB strain. For example, it has been shown that murine DCs can have different responses depending on the strain of LAB and this is further complicated by the fact that these responses can be different even between DC subtypes [<xref rid="B22-vaccines-07-00150" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-07-00150" ref-type="bibr">23</xref>]. This illustrates the complexity in selecting an appropriate LAB strain as a candidate vaccine vector. </p></sec><sec id="sec3-vaccines-07-00150"><title>3. Mucosal Vaccine Adjuvant Strategies</title><p>Robust immune responses to mucosal vaccines have been difficult to achieve. In general, mucosal-delivered vaccines stimulate lower responses compared to systemic vaccines. To overcome this attenuated response, multiple mucosal adjuvants have been identified. Adjuvants of interest include: LAB expression of proteins that stimulate innate immune responses such as pathogen-associated molecular patterns (PAMPs), TLRs, NLRs, retinoic acid-inducible gene-like receptors (RLRs), and C-type lectins, targeting of professional APCs, immune modulating molecules (chemokines, cytokines), and bacterial toxins [<xref rid="B35-vaccines-07-00150" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-07-00150" ref-type="bibr">36</xref>]. Molecular tools have been developed to allow for genetic manipulation of LAB making it possible to express adjuvants in multiple ways such as cell-surface display, secretion, and cytoplasmic [<xref rid="B37-vaccines-07-00150" ref-type="bibr">37</xref>]. The method of display should be carefully considered depending on the adjuvant, its mechanism of action, and the mode of LAB delivery. For instance, an adjuvant could be co-administered with a LAB vaccine that is delivered intranasally or intravaginally while an orally delivered LAB vaccine would encounter the harsh environment of the stomach, making co-administration inappropriate.</p><p>The majority of studies reviewed here used LAB to co-express antigen and adjuvant as opposed to co-administration of a separately produced adjuvant. This method of antigen/adjuvant LAB delivery is not only convenient but is also superior for oral delivery. LAB co-expression of antigen and adjuvant promotes survival of the adjuvant through the stomach and duodenum, enhances interaction with the mucosal surface including delivery to APCs and mucosal immune induction sites, and through colonization of the GI tract, prolonged delivery of the immune stimulating compound. Additionally, through their endogenous immune activation (<xref ref-type="fig" rid="vaccines-07-00150-f001">Figure 1</xref>a), LAB can act in concert with the adjuvant to enhance immune responses.</p><p>The adjuvant strategies that have been employed with LAB vaccine vectors act through diverse mechanisms (<xref ref-type="fig" rid="vaccines-07-00150-f001">Figure 1</xref>b) and evaluation of the adjuvant must be reviewed in the context of the route of delivery, specific LAB vector, and the expression strategy. These factors and the antigen and adjuvant employed, alterations in immune response, and protection against challenge are summarized in <xref ref-type="sec" rid="sec4-vaccines-07-00150">Section 4</xref>, <xref rid="vaccines-07-00150-t001" ref-type="table">Table 1</xref>, <xref rid="vaccines-07-00150-t002" ref-type="table">Table 2</xref>, <xref rid="vaccines-07-00150-t003" ref-type="table">Table 3</xref>, <xref rid="vaccines-07-00150-t004" ref-type="table">Table 4</xref> and <xref rid="vaccines-07-00150-t005" ref-type="table">Table 5</xref>, and <xref ref-type="fig" rid="vaccines-07-00150-f001">Figure 1</xref>b,c.</p></sec><sec id="sec4-vaccines-07-00150"><title>4. Lactic Acid Bacteria Adjuvant Strategies</title><sec id="sec4dot1-vaccines-07-00150"><title>4.1. Cytokine Secretion (<xref rid="vaccines-07-00150-t001" ref-type="table">Table 1</xref>)</title><p>Cytokines act to stimulate and attract immune cells. The selection of a cytokine for use as an adjuvant can be based on the desired immune response to vaccination and its known influence on immune cells. Three cytokines: IL-12, IL-1&#946;, and IL-2 have been investigated for use as adjuvants with LAB vaccines. They have all been utilized as secreted molecules with the exception of one study by Li et al. where IL-12 was delivered as cDNA [<xref rid="B38-vaccines-07-00150" ref-type="bibr">38</xref>]. Cytokine expression strategies, as described below, have generally been successful and there are certainly other cytokines that could be explored. The challenge may be how to express the cytokine adjuvant in such a way that it does not add function to the bacterial vector and does not depend on antibiotic resistance to maintain expression from a plasmid. Cytokine expression could prove to be a challenge in the regulatory approval process.</p><sec id="sec4dot1dot1-vaccines-07-00150"><title>4.1.1. IL-12</title><p>The major sources of IL-12 are monocytes, macrophages, DCs, and neutrophils. The actions of this cytokine are to induce T cell and natural killer (NK) cell proliferation, increase IFN-&#947;, polarize CD4<sup>+</sup> T cells to a Th1 phenotypes, and increase cytotoxicity [<xref rid="B47-vaccines-07-00150" ref-type="bibr">47</xref>]. LAB vaccines supplied with IL-12 have been used against viral induced neoplasia (human papilloma virus) and the intracellular pathogens <italic toggle="yes">Leishmania major</italic> and <italic toggle="yes">Mycobacterium tuberculosis</italic>. Immune responses were greater for the LAB administered with an IL-12 adjuvant as measured by IgG and sIgA (from bronchoalveolar lavage and intestinal wash). Additionally, there was elevated IFN-&#947; and IL-2 (to a lesser extent). IFN-&#947; polarizes T cells to a Th1 phenotype, important in responding to these intracellular pathogens, and IL-2 is important for T cell proliferation. This Th1 polarization is observed in other adjuvant studies reviewed here.</p></sec><sec id="sec4dot1dot2-vaccines-07-00150"><title>4.1.2. IL-1&#946;</title><p>IL-1&#946; is secreted by monocytes and macrophages in response to TLR stimulation. It is secreted in an inactive form and cleaved by activated caspase-1 following assembly of the inflammasome [<xref rid="B48-vaccines-07-00150" ref-type="bibr">48</xref>]. Intracellular activation without secretion of IL-1&#946; can also occur [<xref rid="B49-vaccines-07-00150" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-07-00150" ref-type="bibr">50</xref>]. IL-1&#946; is a pro-inflammatory cytokine and has been shown to act as a mucosal adjuvant [<xref rid="B51-vaccines-07-00150" ref-type="bibr">51</xref>]. It is important in T cell-mediated adaptive immune responses, induces adhesion molecules on mesenchymal and endothelial cells, and is an inducer of the B cell proliferation cytokine IL-6 [<xref rid="B52-vaccines-07-00150" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-07-00150" ref-type="bibr">53</xref>]. The role of IL-1&#946; on T cell-mediated antibody responses is important as T-dependent B cell responses often generate higher-affinity antibodies and increased memory. Secretion of IL-1&#946; has been studied with both <italic toggle="yes">L. casei</italic> and <italic toggle="yes">L. acidophilus</italic>. In both, IL-1&#946; increased IgG and mucosal sIgA when co-expressed with an antigen or delivered with an attenuated antigen (<italic toggle="yes">Salmonella enterica</italic>) [<xref rid="B43-vaccines-07-00150" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-07-00150" ref-type="bibr">44</xref>]. Activated T cells and DCs resulted in increases in the inflammatory cytokines TNF-&#945;, TNF-&#946;, IL-6, and IL-4. The use of IL-1&#946; as an adjuvant may have disadvantages as its pro-inflammatory effects may result in unintended consequences, although none were reported in the studies reviewed here.</p></sec><sec id="sec4dot1dot3-vaccines-07-00150"><title>4.1.3. IL-2</title><p>IL-2 has been used as an adjuvant with <italic toggle="yes">L. lactis</italic> and <italic toggle="yes">L. rhamnosus</italic> GG. IL-2 plays a role in induction of immune responses, specifically proliferation and differentiation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, T regulatory (Treg) cells, and NK cells [<xref rid="B54-vaccines-07-00150" ref-type="bibr">54</xref>]. IL-2 also induces proliferation of intestinal epithelial cells at low concentrations while at high concentrations it can induce epithelial apoptosis. Secreted IL-2 resulted in increased IgG and sIgA and increased trafficking of LAB to mesenteric lymph nodes, an important site for sIgA induction [<xref rid="B45-vaccines-07-00150" ref-type="bibr">45</xref>,<xref rid="B55-vaccines-07-00150" ref-type="bibr">55</xref>]. While increased immune responses were observed using IL-2 as an adjuvant, altered levels of IL-2 have been found in inflammatory bowel disease patients and the complex interaction IL-2 has between inducing tolerance versus inflammation may be problematic for its use as a mucosal adjuvant [<xref rid="B56-vaccines-07-00150" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-07-00150" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-07-00150" ref-type="bibr">58</xref>].</p></sec></sec><sec id="sec4dot2-vaccines-07-00150"><title>4.2. Dendritic Cell (DC) Targeting Adjuvants (<xref rid="vaccines-07-00150-t002" ref-type="table">Table 2</xref>)</title><p>DCs are professional APCs critical for induction of adaptive immune responses and as such are enticing targets to enhance LAB immunogenicity. In the mucosa, DCs play a central role in inducing T and B cells and maintaining the balance of inflammation and tolerance. DCs take up antigens at mucosal surfaces in multiple ways. In the GI tract, DCs sample antigens through M cells or goblet cells, luminal sampling, binding to the neonatal Fc receptor, and apoptotic enterocytes [<xref rid="B59-vaccines-07-00150" ref-type="bibr">59</xref>]. The immune response generated by DCs depends on the method of antigen up-take and pro-inflammatory signals and can result in IgA class switching of B cells, increased sIgA, Th1 and cytotoxic lymphocyte induction, and induction of the mucosal homing integrin &#945;4&#946;7. Due to their importance in inducing mucosal immune responses, adjuvants that target DCs are attractive for use in mucosal delivered vaccines.</p><p>The most common method of targeting DCs with LAB is the surface expression of a DC-peptide attached to an antigen. 12-mer peptides were discovered through screening of a peptide phage display library for binding to the DC cell surface [<xref rid="B60-vaccines-07-00150" ref-type="bibr">60</xref>]. The peptides do not change the function of the DCs but target bound antigens for DCs resulting in the priming of T cells. This has been an active area of investigation with 10 publications evaluating peptide adjuvant qualities. In all these studies, the vaccines were delivered orally with the exception of one intranasal vaccine against avian influenza in chickens [<xref rid="B61-vaccines-07-00150" ref-type="bibr">61</xref>]. Delivery of LAB expressing antigen fused to a DC-peptide resulted in increased DC activation as determined by expression of MHCII, CD80, CD40, and CD86, increased serum IgG and mucosal sIgA, an increased Th1 T cell response, and protection from disease following challenge. DC-peptides seem to induce strong cell-mediated responses in addition to a robust antibody response. One study did report on possible tolerance induction with an increase in the Treg-associated cytokine TGF-&#946; following vaccination and challenge with porcine epidemic diarrhea virus [<xref rid="B62-vaccines-07-00150" ref-type="bibr">62</xref>]. While TGF-&#946; can be associated with Tregs, it can act in concert with IL-6 to induce Th17 cells. Thus, the significance of this finding is unknown, and more studies would be necessary to understand the mechanisms involved in this case.</p><p>Additional strategies have been reported for targeting of LAB mucosal vaccines to DCs, including surface expression of complement C3d3, anti-CD205, and the neonatal Fc receptor (FcRn) [<xref rid="B63-vaccines-07-00150" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-07-00150" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-07-00150" ref-type="bibr">65</xref>]. Of these three methods, only anti-CD205 acts solely by binding to DC cells. C3d3 can also target B cells and FcRn can bind to mucosal epithelial cells and other immune cells [<xref rid="B66-vaccines-07-00150" ref-type="bibr">66</xref>]. These approaches showed similar immune stimulating effects as compared to the DC-peptide adjuvant. Additionally, anti-CD205 was shown to be an effective adjuvant for delivery of a DNA plasmid to DCs and C3d3 acted to increase antibody responses and T and B cell proliferation to an intravaginal contraceptive vaccine. Taken together, DC targeting of LAB is a promising strategy that may also allow tuning of the immune outcome.</p></sec><sec id="sec4dot3-vaccines-07-00150"><title>4.3. Secretion of Bacterial Toxins (<xref rid="vaccines-07-00150-t003" ref-type="table">Table 3</xref>)</title><p>Cholera toxin (CT) and the <italic toggle="yes">E. coli</italic> heat labile enterotoxin (LT) are well-studied mucosal adjuvants that have been used to enhance immune response to antigen delivered by LAB. CT activates DCs and promotes Th2 T cells and B cell isotype switching, while LT promotes antigen presentation and APC-T cell interactions [<xref rid="B79-vaccines-07-00150" ref-type="bibr">79</xref>]. The toxins are composed of two subunits: Active (A) and binding (B) [<xref rid="B35-vaccines-07-00150" ref-type="bibr">35</xref>,<xref rid="B80-vaccines-07-00150" ref-type="bibr">80</xref>]. The use of individual subunits is attractive as it can avoid the unwanted side effects associated with use of the whole toxin [<xref rid="B81-vaccines-07-00150" ref-type="bibr">81</xref>]. The specific mechanisms of cellular and immune system interaction are known for each subunit. The A subunit acts intracellularly to increase cAMP through ADP-ribosylating activity, and the B subunit binds to ganglioside on the surface of most cells. Importantly, the A subunit possesses the toxigenic effects but only when paired with the B subunit [<xref rid="B82-vaccines-07-00150" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-07-00150" ref-type="bibr">83</xref>]. Meanwhile, the B subunit is generally considered non-toxic and enhances antigen-specific immune response through direct binding of immune cells and enhancement of antigen delivery. In the LAB studies reviewed here, CT and LT were delivered as full toxins co-administered with LAB or as individual subunits either surface-displayed or secreted.</p><p>CT and LT LAB adjuvants increased immune responses when compared to LAB mucosal (intranasal or oral) delivered vaccines alone. Outcomes included an increase in IgG and mucosal sIgA, increased protection against pathogen challenge, increased T cell responses (CD4<sup>+</sup> and CD8<sup>+</sup>), and an increase in IFN-&#947;, IL-4, and IL-17. Of interest, studies utilizing CT subunits showed an immune response that was more Th1 polarized (increased IFN-&#947;) while studies using LT as an adjuvant resulted in both Th1 and Th2 responses (increased IFN-&#947; and IL-4) [<xref rid="B84-vaccines-07-00150" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-07-00150" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-07-00150" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-07-00150" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-07-00150" ref-type="bibr">88</xref>].</p><p>The use of CT and LT adjuvants is appealing due to the robust mucosal immune stimulating effects, but in vivo safety remains a serious concern. An example of the toxic effects of CT and LT was demonstrated by the intranasal influenza vaccine, Nasalflu. This vaccine showed increased immune response when delivered with whole LT and no toxicity was observed in clinical trials. Following approval, it was removed from the market after one year of clinical use due to increased incidence of facial paralysis [<xref rid="B89-vaccines-07-00150" ref-type="bibr">89</xref>]. It is possible that this unintended side effect could have been avoided with use of a single LT subunit or if administered through a different mucosal route (orally, for example). No toxicity was reported in the studies reviewed here but, regardless, further toxicity studies are necessary.</p></sec><sec id="sec4dot4-vaccines-07-00150"><title>4.4. Bacterial Derived Adjuvants (<xref rid="vaccines-07-00150-t004" ref-type="table">Table 4</xref>)</title><p>Numerous bacterial proteins have been explored for use with LAB mucosal vaccines. These strategies take advantage of immune activating and invasive proteins that are utilized by pathogenic bacteria, and our considerable knowledge regarding host-bacteria interactions at the molecular level. In many cases the binding domains of bacterial proteins are well-characterized and relatively small, making incorporation of these peptides or short proteins easier to express in a LAB vaccine platform. This provides the opportunity to expand the PRR-activating repertoire and/or enhance interactions between the LAB construct and host.</p><sec id="sec4dot4dot1-vaccines-07-00150"><title>4.4.1. Toll-like Receptor (TLR) 5 Ligand</title><p>TLRs are expressed on many cell types and are an important activator of the innate immune response. TLR5 recognizes flagellin, a component of bacterial flagella, which stimulates production of chemokines and cytokines through myeloid differentiation factor 88 (MyD88) signaling [<xref rid="B15-vaccines-07-00150" ref-type="bibr">15</xref>]. In addition to TLR5 activation, flagellin binds to the cytosolic nucleotide binding oligomerization domain-like receptors (NLR) NLRC4, which leads to caspase-1 inflammasome activation [<xref rid="B106-vaccines-07-00150" ref-type="bibr">106</xref>]. There has been much interest in flagellin as a vaccine adjuvant due to its ease of expression, stability, and robust activation of immune response [<xref rid="B35-vaccines-07-00150" ref-type="bibr">35</xref>,<xref rid="B107-vaccines-07-00150" ref-type="bibr">107</xref>]. There is high expression of TLR5 in the lung, intestinal epithelial cells, monocytes/macrophages, and DCs. Due to this expression pattern, the use of flagellin as a mucosal adjuvant could result in immune activation as well as delivery of an antigen to APCs. Flagellin has been surface-expressed with multiple LAB including: <italic toggle="yes">L. casei</italic>, <italic toggle="yes">L. gasseri</italic>, and <italic toggle="yes">L. acidophilus</italic> [<xref rid="B94-vaccines-07-00150" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-07-00150" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-07-00150" ref-type="bibr">96</xref>]. Oral delivery of LAB expressing antigen and flagellin resulted in increased DC maturation, IgG and mucosal sIgA titers, and increases in both Th1 and Th2 cytokines. While the studies reviewed here only evaluated oral administration, flagellin could be a potent adjuvant for vaccines delivered through other mucosal routes. It has been shown to produce robust immune responses following intranasal delivery and TLR5 is expressed highly in numerous locations of the female reproductive tract, making it attractive for use with intravaginal delivered vaccines [<xref rid="B108-vaccines-07-00150" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-07-00150" ref-type="bibr">109</xref>].</p></sec><sec id="sec4dot4dot2-vaccines-07-00150"><title>4.4.2. Enterocyte Cell Targeting</title><p>Targeting LAB though surface expression of enterocyte binding proteins has been explored with the non-invasive LAB, <italic toggle="yes">L. lactis</italic>, through the use of <italic toggle="yes">Listeria monocytogenes</italic> internalin A (InIA) and/or <italic toggle="yes">Staphylococcus aureus</italic> fibronectin binding protein A (FnBPA) [<xref rid="B97-vaccines-07-00150" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-07-00150" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-07-00150" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-07-00150" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-07-00150" ref-type="bibr">101</xref>]. InlA is a cell wall protein that allows <italic toggle="yes">L. monocytogenes</italic> to bind and be internalized by epithelial cells [<xref rid="B110-vaccines-07-00150" ref-type="bibr">110</xref>]. FnBPA is also an epithelial cell binding protein that can bind to fibrinogen, elastin, and fibronectin allowing for internalization of <italic toggle="yes">S. aureus</italic> into non-phagocytic cells [<xref rid="B111-vaccines-07-00150" ref-type="bibr">111</xref>]. <italic toggle="yes">L. lactis</italic> with cell surface expression of InlA and/or FnBPA has been used to deliver DNA plasmids to intestinal epithelial cells. Delivery of &#946;-lactoglobulin antigen DNA resulted in an increase of &#946;-lactoglobulin within the intestinal lumen, increased Th1 and Th2 cytokine responses, and increased serum and bronchoalveolar fluid IgG and serum IgA (after intranasal delivery of DNA coding for <italic toggle="yes">Mycobacterium tuberculosis</italic> Ag85A) [<xref rid="B98-vaccines-07-00150" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-07-00150" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-07-00150" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-07-00150" ref-type="bibr">101</xref>]. The use of InlA and FnBPA to deliver antigens to epithelial cells may be an effective mucosal vaccine strategy, especially if the desire is to deliver antigen via a eukaryotic expression plasmid (DNA vaccine).</p></sec><sec id="sec4dot4dot3-vaccines-07-00150"><title>4.4.3. Additional Bacterial Derived Adjuvants</title><p>Other bacterial proteins and messengers have been explored as LAB adjuvants. These include: Muramyl dipeptide, <italic toggle="yes">Neisseria meningitidis</italic> PorA, c-di-AMP, and Salmonella resistance to complement killing [<xref rid="B102-vaccines-07-00150" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-07-00150" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-07-00150" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-07-00150" ref-type="bibr">105</xref>]. Addition of these adjuvants to LAB mucosal vaccines resulted in an increased immune response and/or protection to challenge. The mechanism, if known, is described below.</p><p>Muramyl dipeptide (MDP) is a part of the bacterial cell wall and was delivered as a dipeptide with tuftsin, another biologically active compound. As mentioned above, LAB activate NOD2 and this is mediated through MDP breakdown products of the bacterial peptidoglycan. The exact mechanism of immune enhancement by MDP in combination with tuftsin is not fully elucidated but has been shown to activate APCs [<xref rid="B112-vaccines-07-00150" ref-type="bibr">112</xref>].</p><p>PorA is an outer membrane protein from the Gram-negative bacteria <italic toggle="yes">Neisseria meningitidis</italic>. This protein is immunodominant and, while using this protein as a vaccine antigen against <italic toggle="yes">N. meningitidis</italic> has not been successful, it has the potential to act as an adjuvant when conjugated to an antigen. For example, PorA increased the immune response to HpaA antigen from <italic toggle="yes">Helicobacter pylori</italic> [<xref rid="B103-vaccines-07-00150" ref-type="bibr">103</xref>]. The exact mechanism of action of PorA is still under investigation.</p><p>The bacterial second messenger c-di-AMP was evaluated as an intracytoplasmic adjuvant. c-di-AMP has numerous effects on the immune system including type I interferon responses, promotion of Th1 and Th2 responses, increased lymphocyte proliferation, and activation of APCs [<xref rid="B113-vaccines-07-00150" ref-type="bibr">113</xref>]. Delivery of c-di-AMP with an antigen against <italic toggle="yes">Trypanosoma cruzi</italic> resulted in a <italic toggle="yes">T. cruzi</italic>-specific immune response and is proof of concept that LAB can deliver biologically active c-di-AMP.</p><p>Finally, the use of Salmonella resistance to complement killing (RCK) protein was evaluated. This protein is important in interfering with complement killing and invasion into cells, including epithelial cells and APCs [<xref rid="B114-vaccines-07-00150" ref-type="bibr">114</xref>,<xref rid="B115-vaccines-07-00150" ref-type="bibr">115</xref>]. The use of RCK as a mucosal adjuvant was successful in increasing immune responses. The complete mechanism of immune activation is still unknown.</p></sec></sec><sec id="sec4dot5-vaccines-07-00150"><title>4.5. Other Adjuvant Strategies</title><p>There were three LAB adjuvant studies that did not fit into the above categories: Japanese herbal medicines (Juzen-taiho-to (JTT) and Hochi-ekki-to (HEY)), receptor activator of nuclear factor kappa-B ligand (RANKL), and thymosin &#945;-1 [<xref rid="B116-vaccines-07-00150" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-07-00150" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-07-00150" ref-type="bibr">118</xref>]. They are briefly reviewed in <xref rid="vaccines-07-00150-t005" ref-type="table">Table 5</xref> and their mechanisms of action described here.</p><p>The ability of the Japanese herbal medicines JTT and HEY to enhance immune response when co-administered with a <italic toggle="yes">L. casei</italic> oral human papilloma vaccine was evaluated [<xref rid="B116-vaccines-07-00150" ref-type="bibr">116</xref>]. These medicines have been shown to improve immune responses when delivered as an oral or intranasal adjuvant, but the exact mechanism of action is poorly described [<xref rid="B119-vaccines-07-00150" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-07-00150" ref-type="bibr">120</xref>]. When delivered with <italic toggle="yes">L. casei</italic>, there was an increase in Th1 and Th2 cytokines. Other effects on the immune response following vaccination were not reported.</p><p>A study by Kim et al. aimed to increase the immune response to an oral <italic toggle="yes">L. lactis</italic> vaccine against the bacterium <italic toggle="yes">Brachyspira hyodysenteriae</italic> through the secretion of the M cell-inducing protein RANKL [<xref rid="B117-vaccines-07-00150" ref-type="bibr">117</xref>]. M cells are important for pathogen uptake from the intestinal lumen and transport into the Peyer&#8217;s patches [<xref rid="B121-vaccines-07-00150" ref-type="bibr">121</xref>]. <italic toggle="yes">L. lactis</italic> RANKL secretion increased M cell development, serum IgG, and fecal sIgA. This is an interesting adjuvant strategy as it acts through increased transport of the vaccine strain into Peyer&#8217;s patches and not through a pro-inflammatory or DC targeting method.</p><p>Surface-display of the immune-modifier peptide hormone, thymosin &#945;-1, was evaluated as an adjuvant for an orally delivered <italic toggle="yes">L. plantarum</italic> vaccine against classical swine fever [<xref rid="B118-vaccines-07-00150" ref-type="bibr">118</xref>]. This peptide is secreted by the thymus and its use as a vaccine adjuvant has been shown to affect T cell maturation, cytotoxicity, Th1 and Th2 cytokine production, and increase antibody production [<xref rid="B122-vaccines-07-00150" ref-type="bibr">122</xref>,<xref rid="B123-vaccines-07-00150" ref-type="bibr">123</xref>]. Thymosin &#945;-1 as a LAB adjuvant resulted in increased immune responses and protection from viral challenge in pigs.</p></sec></sec><sec sec-type="discussion" id="sec5-vaccines-07-00150"><title>5. Discussion</title><p>LAB have been investigated as potential mucosal vaccine platforms for nearly three decades [<xref rid="B124-vaccines-07-00150" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-07-00150" ref-type="bibr">125</xref>]. Significant progress has been made to explore the inherent immunogenicity of various LAB, develop strategies to express recombinant proteins, and test antigen and adjuvant concepts [<xref rid="B126-vaccines-07-00150" ref-type="bibr">126</xref>]. To date, there is no licensed LAB-based vaccine primarily because necessary immunogenicity, efficacy, and durability have not been achieved. The desperate need for mucosal vaccine platforms continues, as does the promise of approaches that employ LAB. Success will depend on exploiting our current knowledge and emerging technologies. A thoughtful choice of LAB species and strain, antigens, and adjuvant will be required to generate immune protection in the target host. Adjuvants provide tremendous flexibility to direct the nature of the adaptive immune response by supplementing the inherent attributes of LAB. They can target the vaccine construct to a specific cell type, activate particular innate immune pathways, or be selected to drive a desired arm of the adaptive response.</p><p>Highly immunogenic mucosal adjuvants with appropriate safety profiles have been identified and here we reviewed many of these adjuvants in the context of a LAB vaccine vector [<xref rid="B35-vaccines-07-00150" ref-type="bibr">35</xref>,<xref rid="B127-vaccines-07-00150" ref-type="bibr">127</xref>]. LAB were able to produce and display or secrete these adjuvant cytokines, immune targeting peptides, bacterial toxins, and other immune stimulating bacterial proteins. Immune responses after mucosal administration were generally increased in all studies. Specific outcomes included: Increased humoral immune responses (increased IgG and sIgA), increased immune cell proliferation and activation, increased uptake of LAB into immune induction sites, and decreased morbidity and mortality following challenge with bacterial, viral, and parasitic pathogens. Additionally, these adjuvant strategies showed the ability to induce both Th1 and Th2 responses and increase sIgA titers at mucosal sites distant to the site of administration.</p><p>There were other interesting observations in the reviewed studies. The surface display of enterocyte-targeting bacterial proteins by <italic toggle="yes">L. lactis</italic> resulted in delivery of DNA plasmids to enterocytes and protein secretion into the intestinal lumen. This is a potential alternative strategy of protein antigen delivery and could also be utilized to deliver DNA to promote secretion of anti-viral or bacterial peptides [<xref rid="B98-vaccines-07-00150" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-07-00150" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-07-00150" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-07-00150" ref-type="bibr">101</xref>]. Another reported benefit of these bacterial vectors is the ability to outcompete pathogens at mucosal surfaces. An example is a LAB vaccine against Enterotoxigenic <italic toggle="yes">E. coli</italic> (ETEC) with surface display of DC-peptide and ETEC fimbriae. The vector induced increased protective immune responses to ETEC infection and provided immediate protection from pathogen invasion by interfering with attachment of ETEC to intestinal cells [<xref rid="B73-vaccines-07-00150" ref-type="bibr">73</xref>].</p><p>As engineered LAB mucosal vaccines with enhanced immunogenicity are tested in vivo, further investigation is needed into the safety of these strategies. The addition of adjuvants to a vaccine should not cause long-lasting or debilitating local or systemic reactions or induce hypersensitivity reactions, autoimmunity, or neoplasia [<xref rid="B128-vaccines-07-00150" ref-type="bibr">128</xref>]. While LAB are regarded as safe and are used in numerous food products and health supplements, it is unknown if the inclusion of adjuvants would affect their safety profile. No adverse effects were reported in the studies reviewed here despite the use of CT and LT subunits or secretion of pro-inflammatory cytokines. Additionally, it is unknown if repeated exposure to genetically modified LAB would result in unintended immune responses as wild type probiotics are already known to induce and enhance mucosal antibody responses [<xref rid="B129-vaccines-07-00150" ref-type="bibr">129</xref>,<xref rid="B130-vaccines-07-00150" ref-type="bibr">130</xref>]. Whether off-target effects might result in anti-LAB (or other commensal) immune responses should be explored by analyzing the microbial community structure in vaccinated subjects.</p></sec><sec sec-type="conclusions" id="sec6-vaccines-07-00150"><title>6. Conclusions</title><p>The adjuvant strategies reviewed here are diverse and all resulted in increased immune responses. Next-generation LAB have the potential to be powerful mucosal vaccine vectors. Facile techniques that enable multiple genetic modifications, such as CRISPR/Cas, will likely usher in a new era of innovation that may enable the realization of a commercially viable LAB-based mucosal vaccine [<xref rid="B37-vaccines-07-00150" ref-type="bibr">37</xref>,<xref rid="B131-vaccines-07-00150" ref-type="bibr">131</xref>,<xref rid="B132-vaccines-07-00150" ref-type="bibr">132</xref>].</p></sec></body><back><ack><title>Acknowledgments</title><p>Authors would like to thank Molly Pollen for the design of <xref ref-type="fig" rid="vaccines-07-00150-f001">Figure 1</xref> and Alora LaVoy for review of the manuscript.</p></ack><notes><title>Author Contributions</title><p>Conceptualization, A.C.V., G.A.D.; funding acquisition, A.C.V.; investigation, A.C.V.; project administration, G.A.D.; visualization, A.C.V., G.A.D.; writing&#8212;original draft, A.C.V; writing&#8212;review and editing, A.C.V., G.A.D.</p></notes><notes><title>Funding</title><p>This research was funded by the National Institutes of Health under Award Number T32OD010437. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-07-00150"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowiak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Slizewska</surname><given-names>K.</given-names></name></person-group><article-title>Effects of Probiotics, Prebiotics, and Synbiotics on Human Health</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><elocation-id>1021</elocation-id><pub-id pub-id-type="doi">10.3390/nu9091021</pub-id><pub-id pub-id-type="pmid">28914794</pub-id><pub-id pub-id-type="pmcid">PMC5622781</pub-id></element-citation></ref><ref id="B2-vaccines-07-00150"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Passaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gasbarrini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Landolfi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Montalto</surname><given-names>M.</given-names></name></person-group><article-title>Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate</article-title><source>World J. Gastroenterol.</source><year>2016</year><volume>22</volume><fpage>7186</fpage><lpage>7202</lpage><pub-id pub-id-type="doi">10.3748/wjg.v22.i32.7186</pub-id><pub-id pub-id-type="pmid">27621567</pub-id><pub-id pub-id-type="pmcid">PMC4997632</pub-id></element-citation></ref><ref id="B3-vaccines-07-00150"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boirivant</surname><given-names>M.</given-names></name><name name-style="western"><surname>Strober</surname><given-names>W.</given-names></name></person-group><article-title>The mechanism of action of probiotics</article-title><source>Curr. Opin. Gastroenterol.</source><year>2007</year><volume>23</volume><fpage>679</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1097/MOG.0b013e3282f0cffc</pub-id><pub-id pub-id-type="pmid">17906447</pub-id></element-citation></ref><ref id="B4-vaccines-07-00150"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Czerkinsky</surname><given-names>C.</given-names></name></person-group><article-title>Mucosal immunity and vaccines</article-title><source>Nat. Med.</source><year>2005</year><volume>11</volume><fpage>S45</fpage><lpage>S53</lpage><pub-id pub-id-type="doi">10.1038/nm1213</pub-id><pub-id pub-id-type="pmid">15812489</pub-id></element-citation></ref><ref id="B5-vaccines-07-00150"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neutra</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>P.A.</given-names></name></person-group><article-title>Mucosal vaccines: The promise and the challenge</article-title><source>Nat. Rev. Immunol.</source><year>2006</year><volume>6</volume><fpage>148</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/nri1777</pub-id><pub-id pub-id-type="pmid">16491139</pub-id></element-citation></ref><ref id="B6-vaccines-07-00150"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>Y.S.</given-names></name></person-group><article-title>The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants</article-title><source>Clin. Exp. Vaccine Res.</source><year>2017</year><volume>6</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.7774/cevr.2017.6.1.15</pub-id><pub-id pub-id-type="pmid">28168169</pub-id><pub-id pub-id-type="pmcid">PMC5292352</pub-id></element-citation></ref><ref id="B7-vaccines-07-00150"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>The influence of the intestinal microbiome on vaccine responses</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>4433</fpage><lpage>4439</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.04.066</pub-id><pub-id pub-id-type="pmid">29909134</pub-id></element-citation></ref><ref id="B8-vaccines-07-00150"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyaka</surname><given-names>P.N.</given-names></name></person-group><article-title>Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems</article-title><source>J. Immunol.</source><year>2017</year><volume>199</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601775</pub-id><pub-id pub-id-type="pmid">28630108</pub-id><pub-id pub-id-type="pmcid">PMC5719502</pub-id></element-citation></ref><ref id="B9-vaccines-07-00150"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>The influence of probiotics on vaccine responses&#8212;A systematic review</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.08.069</pub-id><pub-id pub-id-type="pmid">28923425</pub-id></element-citation></ref><ref id="B10-vaccines-07-00150"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mercenier</surname><given-names>A.</given-names></name></person-group><article-title>Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria</article-title><source>Nat. Rev. Microbiol.</source><year>2008</year><volume>6</volume><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1840</pub-id><pub-id pub-id-type="pmid">18345021</pub-id><pub-id pub-id-type="pmcid">PMC7096801</pub-id></element-citation></ref><ref id="B11-vaccines-07-00150"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LeCureux</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>G.A.</given-names></name></person-group><article-title>Lactobacillus Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens</article-title><source>mSphere</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1128/mSphere.00061-18</pub-id><pub-id pub-id-type="pmid">29769376</pub-id><pub-id pub-id-type="pmcid">PMC5956152</pub-id></element-citation></ref><ref id="B12-vaccines-07-00150"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Angulo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meza</surname><given-names>B.</given-names></name></person-group><article-title>Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles</article-title><source>Trends Biotechnol.</source><year>2016</year><volume>34</volume><fpage>124</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2015.11.007</pub-id><pub-id pub-id-type="pmid">26708345</pub-id></element-citation></ref><ref id="B13-vaccines-07-00150"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Siber</surname><given-names>G.R.</given-names></name></person-group><article-title>Adjuvants for human vaccines--current status, problems and future prospects</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>1263</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)00011-O</pub-id><pub-id pub-id-type="pmid">8585280</pub-id></element-citation></ref><ref id="B14-vaccines-07-00150"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tregoning</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Kinnear</surname><given-names>E.</given-names></name></person-group><article-title>Adjuvanted influenza vaccines</article-title><source>Hum. Vaccin Immunother.</source><year>2018</year><volume>14</volume><fpage>550</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1415684</pub-id><pub-id pub-id-type="pmid">29232151</pub-id><pub-id pub-id-type="pmcid">PMC5861793</pub-id></element-citation></ref><ref id="B15-vaccines-07-00150"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name></person-group><article-title>Pathogen recognition and innate immunity</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>783</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.015</pub-id><pub-id pub-id-type="pmid">16497588</pub-id></element-citation></ref><ref id="B16-vaccines-07-00150"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girardin</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Boneca</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Viala</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chamaillard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Labigne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Sansonetti</surname><given-names>P.J.</given-names></name></person-group><article-title>Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>8869</fpage><lpage>8872</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200651200</pub-id><pub-id pub-id-type="pmid">12527755</pub-id></element-citation></ref><ref id="B17-vaccines-07-00150"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smits</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Engering</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Kleij</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Schipper</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Capel</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Zaat</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Yazdanbakhsh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wierenga</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>van Kooyk</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin</article-title><source>J. Allergy Clin. Immunol.</source><year>2005</year><volume>115</volume><fpage>1260</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2005.03.036</pub-id><pub-id pub-id-type="pmid">15940144</pub-id></element-citation></ref><ref id="B18-vaccines-07-00150"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konstantinov</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Smidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>de Vos</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Bruijns</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Valence</surname><given-names>F.</given-names></name><name name-style="western"><surname>Molle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lortal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Altermann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klaenhammer</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>19474</fpage><lpage>19479</lpage><pub-id pub-id-type="doi">10.1073/pnas.0810305105</pub-id><pub-id pub-id-type="pmid">19047644</pub-id><pub-id pub-id-type="pmcid">PMC2592362</pub-id></element-citation></ref><ref id="B19-vaccines-07-00150"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawashima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Motohashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shimojo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>N.M.</given-names></name></person-group><article-title>Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity via Interferon-beta from Human Dendritic Cells</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00027</pub-id><pub-id pub-id-type="pmid">29410667</pub-id><pub-id pub-id-type="pmcid">PMC5787129</pub-id></element-citation></ref><ref id="B20-vaccines-07-00150"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>W.</given-names></name></person-group><article-title>Identification and functional characterization of three TLR signaling pathway genes in Cyclina sinensis</article-title><source>Fish Shellfish Immunol.</source><year>2016</year><volume>50</volume><fpage>150</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2016.01.025</pub-id><pub-id pub-id-type="pmid">26804650</pub-id></element-citation></ref><ref id="B21-vaccines-07-00150"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jounai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ikado</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sugimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>D.</given-names></name></person-group><article-title>Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e32588</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032588</pub-id><pub-id pub-id-type="pmid">22505996</pub-id><pub-id pub-id-type="pmcid">PMC3323594</pub-id></element-citation></ref><ref id="B22-vaccines-07-00150"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Frokiaer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pestka</surname><given-names>J.J.</given-names></name></person-group><article-title>Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells</article-title><source>J. Immunol.</source><year>2002</year><volume>168</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.1.171</pub-id><pub-id pub-id-type="pmid">11751960</pub-id></element-citation></ref><ref id="B23-vaccines-07-00150"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Lammers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brigidi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vitali</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rizzello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gionchetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Campieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Stagg</surname><given-names>A.J.</given-names></name></person-group><article-title>Modulation of human dendritic cell phenotype and function by probiotic bacteria</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1602</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.037325</pub-id><pub-id pub-id-type="pmid">15479680</pub-id><pub-id pub-id-type="pmcid">PMC1774301</pub-id></element-citation></ref><ref id="B24-vaccines-07-00150"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebeer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanderleyden</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Keersmaecker</surname><given-names>S.C.</given-names></name></person-group><article-title>Genes and molecules of lactobacilli supporting probiotic action</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2008</year><volume>72</volume><fpage>728</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00017-08</pub-id><pub-id pub-id-type="pmid">19052326</pub-id><pub-id pub-id-type="pmcid">PMC2593565</pub-id></element-citation></ref><ref id="B25-vaccines-07-00150"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanagihara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanaya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hanazato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.R.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>H.</given-names></name></person-group><article-title>Uromodulin-SlpA binding dictates Lactobacillus acidophilus uptake by intestinal epithelial M cells</article-title><source>Int. Immunol.</source><year>2017</year><volume>29</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxx043</pub-id><pub-id pub-id-type="pmid">28992252</pub-id></element-citation></ref><ref id="B26-vaccines-07-00150"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercier-Bonin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chapot-Chartier</surname><given-names>M.P.</given-names></name></person-group><article-title>Surface Proteins of Lactococcus lactis: Bacterial Resources for Muco-adhesion in the Gastrointestinal Tract</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>2247</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.02247</pub-id><pub-id pub-id-type="pmid">29218032</pub-id><pub-id pub-id-type="pmcid">PMC5703838</pub-id></element-citation></ref><ref id="B27-vaccines-07-00150"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otte</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Podolsky</surname><given-names>D.K.</given-names></name></person-group><article-title>Functional modulation of enterocytes by gram-positive and gram-negative microorganisms</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2004</year><volume>286</volume><fpage>G613</fpage><lpage>G626</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00341.2003</pub-id><pub-id pub-id-type="pmid">15010363</pub-id></element-citation></ref><ref id="B28-vaccines-07-00150"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koten</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stange</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Wehkamp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fellermann</surname><given-names>K.</given-names></name></person-group><article-title>Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2</article-title><source>Clin. Exp. Immunol.</source><year>2008</year><volume>151</volume><fpage>528</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2007.03587.x</pub-id><pub-id pub-id-type="pmid">18190603</pub-id><pub-id pub-id-type="pmcid">PMC2276967</pub-id></element-citation></ref><ref id="B29-vaccines-07-00150"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perdigon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maldonado Galdeano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Medici</surname><given-names>M.</given-names></name></person-group><article-title>Interaction of lactic acid bacteria with the gut immune system</article-title><source>Eur. J. Clin. Nutr.</source><year>2002</year><volume>56</volume><issue>Suppl. 4</issue><fpage>S21</fpage><lpage>S26</lpage><pub-id pub-id-type="doi">10.1038/sj.ejcn.1601658</pub-id><pub-id pub-id-type="pmid">12556943</pub-id></element-citation></ref><ref id="B30-vaccines-07-00150"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yam</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>P.</given-names></name><name name-style="western"><surname>N&#8217;Diaye</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cousineau</surname><given-names>B.</given-names></name></person-group><article-title>Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>2689</fpage><lpage>2699</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.03.024</pub-id><pub-id pub-id-type="pmid">18436352</pub-id></element-citation></ref><ref id="B31-vaccines-07-00150"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermudez-Humaran</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Cortes-Perez</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guimaraes</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rabot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alcocer-Gonzalez</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gratadoux</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Rodriguez-Padilla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tamez-Guerra</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Corthier</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>7297</fpage><lpage>7302</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.11.7297</pub-id><pub-id pub-id-type="pmid">16301635</pub-id></element-citation></ref><ref id="B32-vaccines-07-00150"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalina</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Mohamadzadeh</surname><given-names>M.</given-names></name></person-group><article-title>Lactobacilli as natural enhancer of cellular immune response</article-title><source>Discov. Med.</source><year>2005</year><volume>5</volume><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">20704910</pub-id></element-citation></ref><ref id="B33-vaccines-07-00150"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermudez-Humaran</surname><given-names>L.G.</given-names></name></person-group><article-title>Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins</article-title><source>Hum. Vaccines</source><year>2009</year><volume>5</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.4161/hv.5.4.7553</pub-id><pub-id pub-id-type="pmid">19202351</pub-id></element-citation></ref><ref id="B34-vaccines-07-00150"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermudez-Humaran</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Kharrat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chatel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>P.</given-names></name></person-group><article-title>Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines</article-title><source>Microb. Cell Fact.</source><year>2011</year><volume>10</volume><issue>Suppl. 1</issue><fpage>S4</fpage><pub-id pub-id-type="doi">10.1186/1475-2859-10-S1-S4</pub-id><pub-id pub-id-type="pmid">21995317</pub-id><pub-id pub-id-type="pmcid">PMC3231930</pub-id></element-citation></ref><ref id="B35-vaccines-07-00150"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name></person-group><article-title>Mucosal vaccine adjuvants update</article-title><source>Clin. Exp. Vaccine Res.</source><year>2012</year><volume>1</volume><fpage>50</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.7774/cevr.2012.1.1.50</pub-id><pub-id pub-id-type="pmid">23596577</pub-id><pub-id pub-id-type="pmcid">PMC3623511</pub-id></element-citation></ref><ref id="B36-vaccines-07-00150"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freytag</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name></person-group><article-title>Mucosal adjuvants</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1804</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.010</pub-id><pub-id pub-id-type="pmid">15734046</pub-id></element-citation></ref><ref id="B37-vaccines-07-00150"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name></person-group><article-title>Targeting ideal oral vaccine vectors based on probiotics: A systematical view</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2019</year><volume>103</volume><fpage>3941</fpage><lpage>3953</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-09770-7</pub-id><pub-id pub-id-type="pmid">30915504</pub-id></element-citation></ref><ref id="B38-vaccines-07-00150"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice</article-title><source>Oncol. Lett.</source><year>2014</year><volume>7</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1743</pub-id><pub-id pub-id-type="pmid">24396491</pub-id><pub-id pub-id-type="pmcid">PMC3881950</pub-id></element-citation></ref><ref id="B39-vaccines-07-00150"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortes-Perez</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corthier</surname><given-names>G.</given-names></name><name name-style="western"><surname>Adel-Patient</surname><given-names>K.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bermudez-Humaran</surname><given-names>L.G.</given-names></name></person-group><article-title>Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>6581</fpage><lpage>6588</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.06.062</pub-id><pub-id pub-id-type="pmid">17675182</pub-id></element-citation></ref><ref id="B40-vaccines-07-00150"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hugentobler</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Roberto</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cousineau</surname><given-names>B.</given-names></name></person-group><article-title>Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>5726</fpage><lpage>5732</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.07.004</pub-id><pub-id pub-id-type="pmid">22814408</pub-id></element-citation></ref><ref id="B41-vaccines-07-00150"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hugentobler</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yam</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahbuba</surname><given-names>R.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cousineau</surname><given-names>B.</given-names></name></person-group><article-title>Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e30945</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0030945</pub-id><pub-id pub-id-type="pmid">22348031</pub-id><pub-id pub-id-type="pmcid">PMC3277590</pub-id></element-citation></ref><ref id="B42-vaccines-07-00150"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mustafa</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Kalyanasundram</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sabidi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Abdullah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdul Rahim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yusoff</surname><given-names>K.</given-names></name></person-group><article-title>Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice</article-title><source>BMC Biotechnol.</source><year>2018</year><volume>18</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/s12896-018-0461-y</pub-id><pub-id pub-id-type="pmid">30309359</pub-id><pub-id pub-id-type="pmcid">PMC6182793</pub-id></element-citation></ref><ref id="B43-vaccines-07-00150"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kajikawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Igimi</surname><given-names>S.</given-names></name></person-group><article-title>Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1{beta}</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1128/CVI.00337-09</pub-id><pub-id pub-id-type="pmid">19923575</pub-id><pub-id pub-id-type="pmcid">PMC2812087</pub-id></element-citation></ref><ref id="B44-vaccines-07-00150"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kajikawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>LaVoy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bumgardner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klaenhammer</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>G.A.</given-names></name></person-group><article-title>Mucosal Immunogenicity of Genetically Modified Lactobacillus acidophilus Expressing an HIV-1 Epitope within the Surface Layer Protein</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0141713</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0141713</pub-id><pub-id pub-id-type="pmid">26509697</pub-id><pub-id pub-id-type="pmcid">PMC4624987</pub-id></element-citation></ref><ref id="B45-vaccines-07-00150"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandasamy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Selvakumari Jayasurya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moochhala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huat Bay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kun Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mahendran</surname><given-names>R.</given-names></name></person-group><article-title>Lactobacillus rhamnosus GG secreting an antigen and Interleukin-2 translocates across the gastrointestinal tract and induces an antigen specific immune response</article-title><source>Microbiol. Immunol.</source><year>2011</year><volume>55</volume><fpage>704</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1111/j.1348-0421.2011.00370.x</pub-id><pub-id pub-id-type="pmid">21806675</pub-id></element-citation></ref><ref id="B46-vaccines-07-00150"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szatraj</surname><given-names>K.</given-names></name><name name-style="western"><surname>Szczepankowska</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Saczynska</surname><given-names>V.</given-names></name><name name-style="western"><surname>Florys</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gromadzka</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lepek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Plucienniczak</surname><given-names>G.</given-names></name><name name-style="western"><surname>Szewczyk</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zagorski-Ostoja</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bardowski</surname><given-names>J.</given-names></name></person-group><article-title>Expression of avian influenza haemagglutinin (H5) and chicken interleukin 2 (chIL-2) under control of the ptcB promoter in Lactococcus lactis</article-title><source>Acta Biochim. Pol.</source><year>2014</year><volume>61</volume><fpage>609</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.18388/abp.2014_1884</pub-id><pub-id pub-id-type="pmid">25273565</pub-id></element-citation></ref><ref id="B47-vaccines-07-00150"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watford</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Moriguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morinobu</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Shea</surname><given-names>J.J.</given-names></name></person-group><article-title>The biology of IL-12: Coordinating innate and adaptive immune responses</article-title><source>Cytokine Growth Factor Rev.</source><year>2003</year><volume>14</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/S1359-6101(03)00043-1</pub-id><pub-id pub-id-type="pmid">12948519</pub-id></element-citation></ref><ref id="B48-vaccines-07-00150"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinarello</surname><given-names>C.A.</given-names></name></person-group><article-title>Overview of the IL-1 family in innate inflammation and acquired immunity</article-title><source>Immunol. Rev.</source><year>2018</year><volume>281</volume><fpage>8</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/imr.12621</pub-id><pub-id pub-id-type="pmid">29247995</pub-id><pub-id pub-id-type="pmcid">PMC5756628</pub-id></element-citation></ref><ref id="B49-vaccines-07-00150"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conos</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Vaux</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Vince</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Lindqvist</surname><given-names>L.M.</given-names></name></person-group><article-title>Cell death is not essential for caspase-1-mediated interleukin-1beta activation and secretion</article-title><source>Cell Death Differ.</source><year>2016</year><volume>23</volume><fpage>1827</fpage><lpage>1838</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.69</pub-id><pub-id pub-id-type="pmid">27419363</pub-id><pub-id pub-id-type="pmcid">PMC5071572</pub-id></element-citation></ref><ref id="B50-vaccines-07-00150"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boucher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Monteleone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coll</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Holley</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Bierschenk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity</article-title><source>J. Exp. Med.</source><year>2018</year><volume>215</volume><fpage>827</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1084/jem.20172222</pub-id><pub-id pub-id-type="pmid">29432122</pub-id><pub-id pub-id-type="pmcid">PMC5839769</pub-id></element-citation></ref><ref id="B51-vaccines-07-00150"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staats</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Ennis</surname><given-names>F.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens</article-title><source>J. Immunol.</source><year>1999</year><volume>162</volume><fpage>6141</fpage><lpage>6147</lpage><pub-id pub-id-type="pmid">10229857</pub-id></element-citation></ref><ref id="B52-vaccines-07-00150"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Presentini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tagliabue</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghiara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Censini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Volpini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Villa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boraschi</surname><given-names>D.</given-names></name></person-group><article-title>A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity</article-title><source>J. Immunol.</source><year>1986</year><volume>137</volume><fpage>3201</fpage><lpage>3204</lpage><pub-id pub-id-type="pmid">3490514</pub-id></element-citation></ref><ref id="B53-vaccines-07-00150"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shornick</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>De Togni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mariathasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goellner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Strauss-Schoenberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karr</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Chaplin</surname><given-names>D.D.</given-names></name></person-group><article-title>Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone</article-title><source>J. Exp. Med.</source><year>1996</year><volume>183</volume><fpage>1427</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1084/jem.183.4.1427</pub-id><pub-id pub-id-type="pmid">8666901</pub-id><pub-id pub-id-type="pmcid">PMC2192516</pub-id></element-citation></ref><ref id="B54-vaccines-07-00150"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbas</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Simeonov</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Marson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>J.A.</given-names></name></person-group><article-title>Revisiting IL-2: Biology and therapeutic prospects</article-title><source>Sci. Immunol.</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1126/sciimmunol.aat1482</pub-id><pub-id pub-id-type="pmid">29980618</pub-id></element-citation></ref><ref id="B55-vaccines-07-00150"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santiago</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Assis</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Faria</surname><given-names>A.M.</given-names></name></person-group><article-title>Role of mesenteric lymph nodes and aging in secretory IgA production in mice</article-title><source>Cell. Immunol.</source><year>2008</year><volume>253</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2008.06.004</pub-id><pub-id pub-id-type="pmid">18632091</pub-id></element-citation></ref><ref id="B56-vaccines-07-00150"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name></person-group><article-title>Molecular mechanism of interleukin-2-induced mucosal homeostasis</article-title><source>Am. J. Physiol. Cell Physiol.</source><year>2012</year><volume>302</volume><fpage>C735</fpage><lpage>C747</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00316.2011</pub-id><pub-id pub-id-type="pmid">22116305</pub-id><pub-id pub-id-type="pmcid">PMC3311301</pub-id></element-citation></ref><ref id="B57-vaccines-07-00150"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brynskov</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tvede</surname><given-names>N.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Vilien</surname><given-names>M.</given-names></name></person-group><article-title>Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease</article-title><source>Gut</source><year>1992</year><volume>33</volume><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1136/gut.33.1.55</pub-id><pub-id pub-id-type="pmid">1740278</pub-id><pub-id pub-id-type="pmcid">PMC1373865</pub-id></element-citation></ref><ref id="B58-vaccines-07-00150"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pullman</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Doe</surname><given-names>W.F.</given-names></name></person-group><article-title>IL-2 production by intestinal lamina propria cells in normal inflamed and cancer-bearing colons</article-title><source>Clin. Exp. Immunol.</source><year>1992</year><volume>88</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.1992.tb03052.x</pub-id><pub-id pub-id-type="pmid">1563100</pub-id><pub-id pub-id-type="pmcid">PMC1554364</pub-id></element-citation></ref><ref id="B59-vaccines-07-00150"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kweon</surname><given-names>M.N.</given-names></name></person-group><article-title>Mucosal dendritic cells shape mucosal immunity</article-title><source>Exp. Mol. Med.</source><year>2014</year><volume>46</volume><fpage>e84</fpage><pub-id pub-id-type="doi">10.1038/emm.2014.16</pub-id><pub-id pub-id-type="pmid">24626170</pub-id><pub-id pub-id-type="pmcid">PMC3972789</pub-id></element-citation></ref><ref id="B60-vaccines-07-00150"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curiel</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brumlik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Landry</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Finstad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alarez</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lackner</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Peptides identified through phage display direct immunogenic antigen to dendritic cells</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>7425</fpage><lpage>7431</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.12.7425</pub-id><pub-id pub-id-type="pmid">15187120</pub-id></element-citation></ref><ref id="B61-vaccines-07-00150"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.F.</given-names></name></person-group><article-title>Protection of chickens against H9N2 avian influenza virus challenge with recombinant Lactobacillus plantarum expressing conserved antigens</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2017</year><volume>101</volume><fpage>4593</fpage><lpage>4603</lpage><pub-id pub-id-type="doi">10.1007/s00253-017-8230-8</pub-id><pub-id pub-id-type="pmid">28353000</pub-id></element-citation></ref><ref id="B62-vaccines-07-00150"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Min</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Oral Immunization against PEDV with Recombinant Lactobacillus casei Expressing Dendritic Cell-Targeting Peptide Fusing COE Protein of PEDV in Piglets</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.3390/v10030106</pub-id><pub-id pub-id-type="pmid">29494530</pub-id><pub-id pub-id-type="pmcid">PMC5869499</pub-id></element-citation></ref><ref id="B63-vaccines-07-00150"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.J.</given-names></name></person-group><article-title>Molecular adjuvant C3d3 improved the anti-hCGbeta humoral immune response in vaginal inoculation with live recombinant Lactobacillus expressing hCGbeta-C3d3 fusion protein</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>6129</fpage><lpage>6139</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.090</pub-id><pub-id pub-id-type="pmid">17629363</pub-id></element-citation></ref><ref id="B64-vaccines-07-00150"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kuczkowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>P.</given-names></name><name name-style="western"><surname>Eijsink</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Mathiesen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chatel</surname><given-names>J.M.</given-names></name></person-group><article-title>Surface display of an anti-DEC-205 single chain Fv fragment in Lactobacillus plantarum increases internalization and plasmid transfer to dendritic cells in vitro and in vivo</article-title><source>Microb. Cell Fact.</source><year>2015</year><volume>14</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s12934-015-0366-6</pub-id><pub-id pub-id-type="pmid">26141059</pub-id><pub-id pub-id-type="pmcid">PMC4491208</pub-id></element-citation></ref><ref id="B65-vaccines-07-00150"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.F.</given-names></name></person-group><article-title>Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum</article-title><source>Antivir. Res.</source><year>2017</year><volume>138</volume><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.11.025</pub-id><pub-id pub-id-type="pmid">27908830</pub-id></element-citation></ref><ref id="B66-vaccines-07-00150"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roopenian</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Akilesh</surname><given-names>S.</given-names></name></person-group><article-title>FcRn: The neonatal Fc receptor comes of age</article-title><source>Nat. Rev. Immunol.</source><year>2007</year><volume>7</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/nri2155</pub-id><pub-id pub-id-type="pmid">17703228</pub-id></element-citation></ref><ref id="B67-vaccines-07-00150"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamadzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sandwick</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>T.</given-names></name><name name-style="western"><surname>Klaenhammer</surname><given-names>T.R.</given-names></name></person-group><article-title>Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>4331</fpage><lpage>4336</lpage><pub-id pub-id-type="doi">10.1073/pnas.0900029106</pub-id><pub-id pub-id-type="pmid">19246373</pub-id><pub-id pub-id-type="pmcid">PMC2647975</pub-id></element-citation></ref><ref id="B68-vaccines-07-00150"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamadzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Durmaz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pakanati</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Gramarossa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Klaenhammer</surname><given-names>T.R.</given-names></name></person-group><article-title>Targeted expression of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine</article-title><source>Future Microbiol.</source><year>2010</year><volume>5</volume><fpage>1289</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.2217/fmb.10.78</pub-id><pub-id pub-id-type="pmid">20722604</pub-id></element-citation></ref><ref id="B69-vaccines-07-00150"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Construction and immunological evaluation of recombinant Lactobacillus plantarum expressing HN of Newcastle disease virus and DC- targeting peptide fusion protein</article-title><source>J. Biotechnol.</source><year>2015</year><volume>216</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2015.09.033</pub-id><pub-id pub-id-type="pmid">26432338</pub-id></element-citation></ref><ref id="B70-vaccines-07-00150"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Lactobacillus plantarum vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection</article-title><source>Virus Res.</source><year>2016</year><volume>211</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2015.09.005</pub-id><pub-id pub-id-type="pmid">26363195</pub-id></element-citation></ref><ref id="B71-vaccines-07-00150"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.F.</given-names></name></person-group><article-title>Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by Lactobacillus plantarum</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>39665</fpage><pub-id pub-id-type="doi">10.1038/srep39665</pub-id><pub-id pub-id-type="pmid">28004787</pub-id><pub-id pub-id-type="pmcid">PMC5177883</pub-id></element-citation></ref><ref id="B72-vaccines-07-00150"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Oral Delivery of Probiotics Expressing Dendritic Cell-Targeting Peptide Fused with Porcine Epidemic Diarrhea Virus COE Antigen: A Promising Vaccine Strategy against PEDV</article-title><source>Viruses</source><year>2017</year><volume>9</volume><elocation-id>312</elocation-id><pub-id pub-id-type="doi">10.3390/v9110312</pub-id><pub-id pub-id-type="pmid">29068402</pub-id><pub-id pub-id-type="pmcid">PMC5707519</pub-id></element-citation></ref><ref id="B73-vaccines-07-00150"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Alleviation of enterotoxigenic Escherichia coli challenge by recombinant Lactobacillus plantarum expressing a FaeG- and DC-targeting peptide fusion protein</article-title><source>Benef. Microbes</source><year>2017</year><volume>8</volume><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.3920/BM2016.0116</pub-id><pub-id pub-id-type="pmid">28504575</pub-id></element-citation></ref><ref id="B74-vaccines-07-00150"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Construction and immunological evaluation of recombinant Lactobacillus plantarum expressing SO7 of Eimeria tenella fusion DC-targeting peptide</article-title><source>Vet. Parasitol.</source><year>2017</year><volume>236</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2017.01.023</pub-id><pub-id pub-id-type="pmid">28288769</pub-id></element-citation></ref><ref id="B75-vaccines-07-00150"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Colliou</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Valletti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jobin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mohamadzadeh</surname><given-names>M.</given-names></name></person-group><article-title>Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>155</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.11.008</pub-id><pub-id pub-id-type="pmid">29180028</pub-id><pub-id pub-id-type="pmcid">PMC6180320</pub-id></element-citation></ref><ref id="B76-vaccines-07-00150"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Z.</given-names></name><etal/></person-group><article-title>Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide</article-title><source>Virus Res.</source><year>2018</year><volume>247</volume><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2017.12.011</pub-id><pub-id pub-id-type="pmid">29288673</pub-id><pub-id pub-id-type="pmcid">PMC7125666</pub-id></element-citation></ref><ref id="B77-vaccines-07-00150"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus</article-title><source>Microb. Cell Fact.</source><year>2018</year><volume>17</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s12934-018-0861-7</pub-id><pub-id pub-id-type="pmid">29426335</pub-id><pub-id pub-id-type="pmcid">PMC5807822</pub-id></element-citation></ref><ref id="B78-vaccines-07-00150"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Dendritic Cell Targeting of Bovine Viral Diarrhea Virus E2 Protein Expressed by Lactobacillus casei Effectively Induces Antigen-Specific Immune Responses via Oral Vaccination</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>575</elocation-id><pub-id pub-id-type="doi">10.3390/v11060575</pub-id><pub-id pub-id-type="pmcid">PMC6630502</pub-id><pub-id pub-id-type="pmid">31242608</pub-id></element-citation></ref><ref id="B79-vaccines-07-00150"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hajishengallis</surname><given-names>G.</given-names></name></person-group><article-title>Heat-labile enterotoxins as adjuvants or anti-inflammatory agents</article-title><source>Immunol. Investig</source><year>2010</year><volume>39</volume><fpage>449</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.3109/08820130903563998</pub-id><pub-id pub-id-type="pmid">20461887</pub-id><pub-id pub-id-type="pmcid">PMC2819675</pub-id></element-citation></ref><ref id="B80-vaccines-07-00150"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs</article-title><source>Drug Saf.</source><year>2015</year><volume>38</volume><fpage>1059</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1007/s40264-015-0350-4</pub-id><pub-id pub-id-type="pmid">26446142</pub-id><pub-id pub-id-type="pmcid">PMC4615573</pub-id></element-citation></ref><ref id="B81-vaccines-07-00150"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajishengallis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arce</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gockel</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Connell</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>M.W.</given-names></name></person-group><article-title>Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: Applications for oral infections</article-title><source>J. Dent. Res.</source><year>2005</year><volume>84</volume><fpage>1104</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1177/154405910508401205</pub-id><pub-id pub-id-type="pmid">16304439</pub-id></element-citation></ref><ref id="B82-vaccines-07-00150"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lowenadler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>N.</given-names></name></person-group><article-title>A novel concept in mucosal adjuvanticity: The CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit</article-title><source>Immunol. Cell Biol.</source><year>1998</year><volume>76</volume><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1711.1998.00750.x</pub-id><pub-id pub-id-type="pmid">9682972</pub-id></element-citation></ref><ref id="B83-vaccines-07-00150"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sverremark</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ekman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lowenadler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>N.</given-names></name></person-group><article-title>The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects</article-title><source>J. Immunol.</source><year>2000</year><volume>164</volume><fpage>6276</fpage><lpage>6286</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.12.6276</pub-id><pub-id pub-id-type="pmid">10843681</pub-id></element-citation></ref><ref id="B84-vaccines-07-00150"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B</article-title><source>Clin. Vaccine Immunol.</source><year>2011</year><volume>18</volume><fpage>1046</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1128/CVI.00050-11</pub-id><pub-id pub-id-type="pmid">21632890</pub-id><pub-id pub-id-type="pmcid">PMC3147322</pub-id></element-citation></ref><ref id="B85-vaccines-07-00150"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Pathinayake</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weeratunga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Song</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Son</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.P.</given-names></name><etal/></person-group><article-title>Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e94051</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0094051</pub-id><pub-id pub-id-type="pmid">24714362</pub-id><pub-id pub-id-type="pmcid">PMC3979752</pub-id></element-citation></ref><ref id="B86-vaccines-07-00150"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Pathinayake</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koo</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.P.</given-names></name><etal/></person-group><article-title>Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes</article-title><source>Vet. Microbiol.</source><year>2015</year><volume>179</volume><fpage>250</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2015.07.020</pub-id><pub-id pub-id-type="pmid">26210951</pub-id></element-citation></ref><ref id="B87-vaccines-07-00150"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name></person-group><article-title>Construction of recombinant lactobacilli expressing the core neutralizing epitope (COE) of porcine epidemic diarrhea virus and a fusion protein consisting of COE and Escherichia coli heat-labile enterotoxin B, and comparison of the immune responses by orogastric immunization</article-title><source>Can. J. Microbiol.</source><year>2012</year><volume>58</volume><fpage>1258</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1139/w2012-098</pub-id><pub-id pub-id-type="pmid">23145823</pub-id></element-citation></ref><ref id="B88-vaccines-07-00150"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Molecular mechanisms underlying protection against H9N2 influenza virus challenge in mice by recombinant Lactobacillus plantarum with surface displayed HA2-LTB</article-title><source>J. Biotechnol.</source><year>2017</year><volume>259</volume><fpage>6</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2017.08.011</pub-id><pub-id pub-id-type="pmid">28811215</pub-id></element-citation></ref><ref id="B89-vaccines-07-00150"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Linder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spyr</surname><given-names>C.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>R.</given-names></name></person-group><article-title>Use of the inactivated intranasal influenza vaccine and the risk of Bell&#8217;s palsy in Switzerland</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>896</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030595</pub-id><pub-id pub-id-type="pmid">14985487</pub-id></element-citation></ref><ref id="B90-vaccines-07-00150"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Monedero</surname><given-names>V.</given-names></name><name name-style="western"><surname>Perez-Martinez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>P.L.</given-names></name></person-group><article-title>Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in Lactobacillus casei</article-title><source>Curr. Microbiol.</source><year>2006</year><volume>53</volume><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1007/s00284-005-0388-0</pub-id><pub-id pub-id-type="pmid">17106803</pub-id></element-citation></ref><ref id="B91-vaccines-07-00150"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okuno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kashige</surname><given-names>N.</given-names></name><name name-style="western"><surname>Satho</surname><given-names>T.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hiramatsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sharmin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukumitsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Uyeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harakuni</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Expression and secretion of cholera toxin B subunit in lactobacilli</article-title><source>Biol. Pharm. Bull.</source><year>2013</year><volume>36</volume><fpage>952</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1248/bpb.b12-01021</pub-id><pub-id pub-id-type="pmid">23727916</pub-id></element-citation></ref><ref id="B92-vaccines-07-00150"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice</article-title><source>BMC Microbiol.</source><year>2009</year><volume>9</volume><elocation-id>249</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-9-249</pub-id><pub-id pub-id-type="pmid">19958557</pub-id><pub-id pub-id-type="pmcid">PMC2797526</pub-id></element-citation></ref><ref id="B93-vaccines-07-00150"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Immunogenicity of recombinant Lactobacillus casei-expressing F4 (K88) fimbrial adhesin FaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic Escherichia coli as an oral adjuvant in mice</article-title><source>J. Appl. Microbiol.</source><year>2017</year><volume>122</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1111/jam.13352</pub-id><pub-id pub-id-type="pmid">27860074</pub-id></element-citation></ref><ref id="B94-vaccines-07-00150"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kajikawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Igimi</surname><given-names>S.</given-names></name></person-group><article-title>Innate and acquired immune responses induced by recombinant Lactobacillus casei displaying flagellin-fusion antigen on the cell-surface</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>3409</fpage><lpage>3415</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.077</pub-id><pub-id pub-id-type="pmid">20197143</pub-id></element-citation></ref><ref id="B95-vaccines-07-00150"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoeker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nordone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gunderson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kajikawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>LaVoy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klaenhammer</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>G.A.</given-names></name></person-group><article-title>Assessment of Lactobacillus gasseri as a candidate oral vaccine vector</article-title><source>Clin. Vaccine Immunol.</source><year>2011</year><volume>18</volume><fpage>1834</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1128/CVI.05277-11</pub-id><pub-id pub-id-type="pmid">21900526</pub-id><pub-id pub-id-type="pmcid">PMC3209016</pub-id></element-citation></ref><ref id="B96-vaccines-07-00150"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kajikawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Long</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nordone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stoeker</surname><given-names>L.</given-names></name><name name-style="western"><surname>LaVoy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bumgardner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klaenhammer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>G.</given-names></name></person-group><article-title>Construction and immunological evaluation of dual cell surface display of HIV-1 gag and Salmonella enterica serovar Typhimurium FliC in Lactobacillus acidophilus for vaccine delivery</article-title><source>Clin. Vaccine Immunol.</source><year>2012</year><volume>19</volume><fpage>1374</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1128/CVI.00049-12</pub-id><pub-id pub-id-type="pmid">22761297</pub-id><pub-id pub-id-type="pmcid">PMC3428403</pub-id></element-citation></ref><ref id="B97-vaccines-07-00150"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guimaraes</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cabanes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gruss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cossart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>P.</given-names></name></person-group><article-title>Internalin-expressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells</article-title><source>Microbes Infect.</source><year>2005</year><volume>7</volume><fpage>836</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2005.02.012</pub-id><pub-id pub-id-type="pmid">15878681</pub-id></element-citation></ref><ref id="B98-vaccines-07-00150"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Azevedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karczewski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chatel</surname><given-names>J.M.</given-names></name></person-group><article-title>In vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes Internalin, A</article-title><source>BMC Microbiol.</source><year>2012</year><volume>12</volume><fpage>299</fpage><pub-id pub-id-type="doi">10.1186/1471-2180-12-299</pub-id><pub-id pub-id-type="pmid">23253484</pub-id><pub-id pub-id-type="pmcid">PMC3541092</pub-id></element-citation></ref><ref id="B99-vaccines-07-00150"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pontes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Innocentin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Del Carmen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Leblanc</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>de Moreno de Leblanc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blugeon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cherbuy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Production of Fibronectin Binding Protein A at the surface of Lactococcus lactis increases plasmid transfer in vitro and in vivo</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e44892</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044892</pub-id><pub-id pub-id-type="pmid">23028664</pub-id><pub-id pub-id-type="pmcid">PMC3459934</pub-id></element-citation></ref><ref id="B100-vaccines-07-00150"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pontes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Innocentin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blugeon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Courtin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chapot-Chartier</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Immune response elicited by DNA vaccination using Lactococcus lactis is modified by the production of surface exposed pathogenic protein</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e84509</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0084509</pub-id><pub-id pub-id-type="pmid">24465412</pub-id><pub-id pub-id-type="pmcid">PMC3897362</pub-id></element-citation></ref><ref id="B101-vaccines-07-00150"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancha-Agresti</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Castro</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>J.S.C.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>V.B.</given-names></name><name name-style="western"><surname>LeBlanc</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Leclercq</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V.</given-names></name></person-group><article-title>Recombinant Invasive Lactococcus lactis Carrying a DNA Vaccine Coding the Ag85A Antigen Increases INF-gamma, IL-6, and TNF-alpha Cytokines after Intranasal Immunization</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>1263</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01263</pub-id><pub-id pub-id-type="pmid">28744263</pub-id><pub-id pub-id-type="pmcid">PMC5504179</pub-id></element-citation></ref><ref id="B102-vaccines-07-00150"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Up-regulation of MDP and tuftsin gene expression in Th1 and Th17 cells as an adjuvant for an oral Lactobacillus casei vaccine against anti-transmissible gastroenteritis virus</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2014</year><volume>98</volume><fpage>8301</fpage><lpage>8312</lpage><pub-id pub-id-type="doi">10.1007/s00253-014-5893-2</pub-id><pub-id pub-id-type="pmid">24993357</pub-id></element-citation></ref><ref id="B103-vaccines-07-00150"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasquez</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Manzo</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Barrientos</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Mosqueira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Avila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Touma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant</article-title><source>Hum. Vaccin Immunother.</source><year>2015</year><volume>11</volume><fpage>776</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1011011</pub-id><pub-id pub-id-type="pmid">25750999</pub-id><pub-id pub-id-type="pmcid">PMC4514328</pub-id></element-citation></ref><ref id="B104-vaccines-07-00150"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quintana</surname><given-names>I.</given-names></name><name name-style="western"><surname>Espariz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villar</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Pacini</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bontempi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prochetto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stulke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3&#8217; 5&#8217;- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2100</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02100</pub-id><pub-id pub-id-type="pmid">30258417</pub-id><pub-id pub-id-type="pmcid">PMC6143824</pub-id></element-citation></ref><ref id="B105-vaccines-07-00150"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Neutralizing-antibody-mediated protection of chickens against infectious bursal disease via one-time vaccination with inactivated recombinant Lactococcus lactis expressing a fusion protein constructed from the RCK protein of Salmonella enterica and VP2 of infectious bursal disease virus</article-title><source>Microb. Cell Fact.</source><year>2019</year><volume>18</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12934-019-1061-9</pub-id><pub-id pub-id-type="pmid">30704494</pub-id><pub-id pub-id-type="pmcid">PMC6357496</pub-id></element-citation></ref><ref id="B106-vaccines-07-00150"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Alpuche-Aranda</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Dors</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf</article-title><source>Nat. Immunol.</source><year>2006</year><volume>7</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/ni1344</pub-id><pub-id pub-id-type="pmid">16648853</pub-id></element-citation></ref><ref id="B107-vaccines-07-00150"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Flagellin as a vaccine adjuvant</article-title><source>Expert Rev. Vaccines</source><year>2018</year><volume>17</volume><fpage>335</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1080/14760584.2018.1457443</pub-id><pub-id pub-id-type="pmid">29580106</pub-id></element-citation></ref><ref id="B108-vaccines-07-00150"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Fujihashi</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>466</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.10.058</pub-id><pub-id pub-id-type="pmid">22051136</pub-id></element-citation></ref><ref id="B109-vaccines-07-00150"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fazeli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anumba</surname><given-names>D.O.</given-names></name></person-group><article-title>Characterization of Toll-like receptors in the female reproductive tract in humans</article-title><source>Hum. Reprod.</source><year>2005</year><volume>20</volume><fpage>1372</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1093/humrep/deh775</pub-id><pub-id pub-id-type="pmid">15695310</pub-id></element-citation></ref><ref id="B110-vaccines-07-00150"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaillard</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Berche</surname><given-names>P.</given-names></name><name name-style="western"><surname>Frehel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gouin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cossart</surname><given-names>P.</given-names></name></person-group><article-title>Entry of L. monocytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci</article-title><source>Cell</source><year>1991</year><volume>65</volume><fpage>1127</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90009-N</pub-id><pub-id pub-id-type="pmid">1905979</pub-id></element-citation></ref><ref id="B111-vaccines-07-00150"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Innocentin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guimaraes</surname><given-names>V.</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chatel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>F.</given-names></name></person-group><article-title>Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells</article-title><source>Appl. Environ. Microbiol.</source><year>2009</year><volume>75</volume><fpage>4870</fpage><lpage>4878</lpage><pub-id pub-id-type="doi">10.1128/AEM.00825-09</pub-id><pub-id pub-id-type="pmid">19482952</pub-id><pub-id pub-id-type="pmcid">PMC2708419</pub-id></element-citation></ref><ref id="B112-vaccines-07-00150"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dzierzbicka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Menderska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trzonkowski</surname><given-names>P.</given-names></name></person-group><article-title>New conjugates of tuftsin and muramyl dipeptide as stimulators of human monocyte-derived dendritic cells</article-title><source>Protein Pept. Lett.</source><year>2013</year><volume>20</volume><fpage>200</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.2174/092986613804725299</pub-id><pub-id pub-id-type="pmid">22894158</pub-id></element-citation></ref><ref id="B113-vaccines-07-00150"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skrnjug</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rueckert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Libanova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lienenklaus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name></person-group><article-title>The mucosal adjuvant cyclic di-AMP exerts immune stimulatory effects on dendritic cells and macrophages</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e95728</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0095728</pub-id><pub-id pub-id-type="pmid">24755640</pub-id><pub-id pub-id-type="pmcid">PMC3996008</pub-id></element-citation></ref><ref id="B114-vaccines-07-00150"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heffernan</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fierer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roudier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guiney</surname><given-names>D.</given-names></name></person-group><article-title>Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck</article-title><source>J. Clin. Investig.</source><year>1992</year><volume>90</volume><fpage>953</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1172/JCI115972</pub-id><pub-id pub-id-type="pmid">1522243</pub-id><pub-id pub-id-type="pmcid">PMC329951</pub-id></element-citation></ref><ref id="B115-vaccines-07-00150"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosselin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Virlogeux-Payant</surname><given-names>I.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bottreau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sizaret</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Mijouin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Germon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>E.</given-names></name><name name-style="western"><surname>Velge</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wiedemann</surname><given-names>A.</given-names></name></person-group><article-title>Rck of Salmonella enterica, subspecies enterica serovar enteritidis, mediates zipper-like internalization</article-title><source>Cell Res.</source><year>2010</year><volume>20</volume><fpage>647</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1038/cr.2010.45</pub-id><pub-id pub-id-type="pmid">20368731</pub-id></element-citation></ref><ref id="B116-vaccines-07-00150"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taguchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawana</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tomio</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kojima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kozuma</surname><given-names>S.</given-names></name></person-group><article-title>Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>5368</fpage><lpage>5372</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.06.027</pub-id><pub-id pub-id-type="pmid">22727726</pub-id></element-citation></ref><ref id="B117-vaccines-07-00150"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Park</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Maharjan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Piao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Bok</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Soluble RANKL expression in Lactococcus lactis and investigation of its potential as an oral vaccine adjuvant</article-title><source>BMC Immunol.</source><year>2015</year><volume>16</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.1186/s12865-015-0132-x</pub-id><pub-id pub-id-type="pmid">26608025</pub-id><pub-id pub-id-type="pmcid">PMC4659156</pub-id></element-citation></ref><ref id="B118-vaccines-07-00150"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.G.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.C.</given-names></name></person-group><article-title>Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin alpha-1 as an Adjuvant</article-title><source>Appl. Environ. Microbiol.</source><year>2015</year><volume>81</volume><fpage>3745</fpage><lpage>3752</lpage><pub-id pub-id-type="doi">10.1128/AEM.00127-15</pub-id><pub-id pub-id-type="pmid">25819954</pub-id><pub-id pub-id-type="pmcid">PMC4421069</pub-id></element-citation></ref><ref id="B119-vaccines-07-00150"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Underwood</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Chivers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Licciardi</surname><given-names>P.V.</given-names></name></person-group><article-title>Stimulation of tetanus toxoid-specific immune responses by a traditional Chinese herbal medicine</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>6634</fpage><lpage>6641</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.03.051</pub-id><pub-id pub-id-type="pmid">19781825</pub-id></element-citation></ref><ref id="B120-vaccines-07-00150"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiyohara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Munakata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nonaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hanawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H.</given-names></name></person-group><article-title>Stimulating effect of Japanese herbal (kampo) medicine, hochuekkito on upper respiratory mucosal immune system</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2006</year><volume>3</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1093/ecam/nel030</pub-id><pub-id pub-id-type="pmcid">PMC1697741</pub-id><pub-id pub-id-type="pmid">17173109</pub-id></element-citation></ref><ref id="B121-vaccines-07-00150"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Roles of M cells in infection and mucosal vaccines</article-title><source>Hum. Vaccin Immunother.</source><year>2014</year><volume>10</volume><fpage>3544</fpage><lpage>3551</lpage><pub-id pub-id-type="doi">10.4161/hv.36174</pub-id><pub-id pub-id-type="pmid">25483705</pub-id><pub-id pub-id-type="pmcid">PMC4514083</pub-id></element-citation></ref><ref id="B122-vaccines-07-00150"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.Q.</given-names></name></person-group><article-title>Effect of thymosin-alpha(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B</article-title><source>J. Int. Med. Res.</source><year>2010</year><volume>38</volume><fpage>2053</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1177/147323001003800620</pub-id><pub-id pub-id-type="pmid">21227010</pub-id></element-citation></ref><ref id="B123-vaccines-07-00150"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saibara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nemoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ono</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akisawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>S.</given-names></name></person-group><article-title>Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts</article-title><source>Int. Immunopharmacol.</source><year>2002</year><volume>2</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S1567-5769(01)00136-9</pub-id><pub-id pub-id-type="pmid">11789668</pub-id></element-citation></ref><ref id="B124-vaccines-07-00150"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerritse</surname><given-names>K.</given-names></name><name name-style="western"><surname>Posno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schellekens</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Boersma</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Claassen</surname><given-names>E.</given-names></name></person-group><article-title>Oral administration of TNP-Lactobacillus conjugates in mice: A model for evaluation of mucosal and systemic immune responses and memory formation elicited by transformed lactobacilli</article-title><source>Res. Microbiol.</source><year>1990</year><volume>141</volume><fpage>955</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1016/0923-2508(90)90135-D</pub-id><pub-id pub-id-type="pmid">2101487</pub-id></element-citation></ref><ref id="B125-vaccines-07-00150"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marteau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rambaud</surname><given-names>J.C.</given-names></name></person-group><article-title>Potential of using lactic acid bacteria for therapy and immunomodulation in man</article-title><source>FEMS Microbiol. Rev.</source><year>1993</year><volume>12</volume><fpage>207</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.1993.tb00019.x</pub-id><pub-id pub-id-type="pmid">8398215</pub-id></element-citation></ref><ref id="B126-vaccines-07-00150"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Orito</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tokunoh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>N.</given-names></name></person-group><article-title>Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2019</year><volume>103</volume><fpage>5947</fpage><lpage>5955</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-09912-x</pub-id><pub-id pub-id-type="pmid">31175431</pub-id></element-citation></ref><ref id="B127-vaccines-07-00150"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apostolico Jde</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lunardelli</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Coirada</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Boscardin</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.S.</given-names></name></person-group><article-title>Adjuvants: Classification, Modus Operandi, and Licensing</article-title><source>J. Immunol. Res.</source><year>2016</year><volume>2016</volume><fpage>1459394</fpage><pub-id pub-id-type="doi">10.1155/2016/1459394</pub-id><pub-id pub-id-type="pmid">27274998</pub-id><pub-id pub-id-type="pmcid">PMC4870346</pub-id></element-citation></ref><ref id="B128-vaccines-07-00150"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edelman</surname><given-names>R.</given-names></name></person-group><article-title>Vaccine adjuvants</article-title><source>Rev. Infect. Dis.</source><year>1980</year><volume>2</volume><fpage>370</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1093/clinids/2.3.370</pub-id><pub-id pub-id-type="pmid">6997966</pub-id></element-citation></ref><ref id="B129-vaccines-07-00150"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umesaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Setoyama</surname><given-names>H.</given-names></name></person-group><article-title>Structure of the intestinal flora responsible for development of the gut immune system in a rodent model</article-title><source>Microbes Infect.</source><year>2000</year><volume>2</volume><fpage>1343</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(00)01288-0</pub-id><pub-id pub-id-type="pmid">11018451</pub-id></element-citation></ref><ref id="B130-vaccines-07-00150"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lyon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Beal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Foey</surname><given-names>A.D.</given-names></name></person-group><article-title>Probiotics, prebiotics and immunomodulation of gut mucosal defences: Homeostasis and immunopathology</article-title><source>Nutrients</source><year>2013</year><volume>5</volume><fpage>1869</fpage><lpage>1912</lpage><pub-id pub-id-type="doi">10.3390/nu5061869</pub-id><pub-id pub-id-type="pmid">23760057</pub-id><pub-id pub-id-type="pmcid">PMC3725482</pub-id></element-citation></ref><ref id="B131-vaccines-07-00150"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stout</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klaenhammer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barrangou</surname><given-names>R.</given-names></name></person-group><article-title>CRISPR-Cas Technologies and Applications in Food Bacteria</article-title><source>Annu. Rev. Food Sci. Technol.</source><year>2017</year><volume>8</volume><fpage>413</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1146/annurev-food-072816-024723</pub-id><pub-id pub-id-type="pmid">28245154</pub-id></element-citation></ref><ref id="B132-vaccines-07-00150"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Pijkeren</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Barrangou</surname><given-names>R.</given-names></name></person-group><article-title>Genome Editing of Food-Grade Lactobacilli to Develop Therapeutic Probiotics</article-title><source>Microbiol. Spectr.</source><year>2017</year><volume>5</volume><pub-id pub-id-type="doi">10.1128/microbiolspec.BAD-0013-2016</pub-id><pub-id pub-id-type="pmcid">PMC5958611</pub-id><pub-id pub-id-type="pmid">28959937</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-07-00150-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Lactic acid bacteria (LAB) interactions with the mucosa and mucosal immune system. (<bold>a</bold>) Endogenous LAB mucosal interactions. LAB possess the ability to bind to mucus (<bold>1</bold>), epithelial cells, and microfold (M) cells (<bold>2</bold>) allowing for uptake into mucosal associated lymphoid tissue (MALT) and trafficking to local lymph nodes (<bold>4</bold>) [<xref rid="B24-vaccines-07-00150" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-07-00150" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-07-00150" ref-type="bibr">26</xref>]. The interactions of LAB with the epithelium can induce epithelial defenses such as the secretion of &#946;-defensin (<bold>3</bold>) [<xref rid="B27-vaccines-07-00150" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-07-00150" ref-type="bibr">28</xref>]. LAB can activate macrophages (<bold>8</bold>) and dendritic cells (DCs) (<bold>5</bold>), which can traffic phagocytosed LAB to local immune induction sites (<bold>4</bold>) [<xref rid="B29-vaccines-07-00150" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-07-00150" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-07-00150" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-07-00150" ref-type="bibr">32</xref>]. LAB also induce effector immune responses such as polarization of na&#239;ve T cells to Th1, Th2, and Treg cells (<bold>6</bold>) and humoral responses such as B cell proliferation, class switching to IgG and IgA, induction of long-lived plasma cells, and induction of the mucosal homing integrin &#945;4&#946;7 (<bold>7</bold>) [<xref rid="B33-vaccines-07-00150" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-07-00150" ref-type="bibr">34</xref>]. (<bold>b</bold>) LAB mucosal adjuvant strategies. (<bold>1</bold>) LAB secretion of pro-inflammatory cytokines such as IL-12, IL-1&#946;, and IL-2 activates T cells, NK cells, and B cells, induces epithelial cell adhesion molecule expression, and promotes trafficking of LAB to local lymph nodes. (<bold>2</bold>) LAB surface expression of the epithelial cell adhesion molecules InlA and/or FnBPA promotes binding and uptake of LAB by epithelial cells, delivery of eukaryotic expression plasmid, and secretion of protein. (<bold>3</bold>) LAB surface expression of DC-binding peptides results in targeting, increased uptake, and activation of DCs as well as trafficking to local immune induction sites. (<bold>4</bold>) Surface expression of LT or CT B subunit results in LAB binding to gangliosides on the surface of epithelial cells and DCs. Co-delivery of full toxins or CT/LT A subunit results in a pro-inflammatory response. (<bold>5</bold>) Surface-expressed flagellin, a TLR5 ligand, induces cytokine production by epithelial cells and direct activation of DCs. (<bold>6</bold>) LAB secretion of RANKL results in increased M cells and uptake of LAB into MALT. (<bold>c</bold>) Review of the effects of adjuvants on the immune response to LAB mucosal vaccination. LAB: Lactic acid bacteria; DC: Dendritic cell; M&#981;: Macrophage; MALT: Mucosal-associated lymphoid tissue; pIgA: Polymeric immunoglobulin receptor; sIgA: Secretory IgA; NK cells: Natural killer cells; M cells: Microfold cells; TLR: Toll-like receptor; RANKL: Receptor activator of nuclear factor kappa-B ligand; InlA: <italic toggle="yes">Listeria monocytogenes</italic> internalin A; FnBPA: Fibronectin-binding protein A; CT: Cholera toxin; LT: <italic toggle="yes">E. coli</italic> heat-labile toxin</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-07-00150-g001a.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-07-00150-g001b.jpg"/></fig><table-wrap id="vaccines-07-00150-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-07-00150-t001_Table 1</object-id><label>Table 1</label><caption><p>Cytokine adjuvant strategies for lactic acid bacteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LAB</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th></tr></thead><tbody><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>IL-12</bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-12</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Human Papilloma Virus (E7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased BAL IgG and sIgA </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intranasal</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine C57BL/6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bermudez-Humaran et al. 2005 [<xref rid="B31-vaccines-07-00150" ref-type="bibr">31</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947; CD4<sup>+</sup> and 8<sup>+</sup> T cells</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-12</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
<break/>
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Human Papilloma Virus (E7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">L. lactis</italic>, Intranasal Delivery</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intranasal Oral</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine C57BL/6</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cortes-Perez et al. 2007 [<xref rid="B39-vaccines-07-00150" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Increased Serum and GAL IgG; Increased GAL IgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">L. plantarum</italic>, Intranasal Delivery</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Increased IFN-&#947; </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased Tumor Burden</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-12</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Leishmania major Leishmania</italic> (Homologue of Activated C Kinase)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Subcutaneous Oral</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hugentobler et al. 2012 [<xref rid="B40-vaccines-07-00150" ref-type="bibr">40</xref>] <break/>Hugentobler et al. 2012 [<xref rid="B41-vaccines-07-00150" ref-type="bibr">41</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Increased IgG1 and IgG2a</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Increased IFN-&#947;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased Parasite Load</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Decreased Parasite Load</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Increased Intestinal sIgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IL-2</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-12</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cytoplasmic (DNA)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Human Papilloma Virus (E7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intranasal</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine C57BL/6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Li et al. 2014 [<xref rid="B38-vaccines-07-00150" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased Tumor Volume</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-12</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
<break/>
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted (by <italic toggle="yes">L. lactis</italic> with <italic toggle="yes">L. plantarum</italic> Expressing the Antigen)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic><break/>(Subunit Epitopes: Ag85B, CFP-10, ESAT-6, Rv0475, Rv2031c)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mustafa et al. 2018 [<xref rid="B42-vaccines-07-00150" ref-type="bibr">42</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IL-2</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>IL-1</bold>
<bold>&#946;</bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-1&#946;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Salmonella enterica</italic> (SE)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-6, TNF-&#945;, TGF-&#946;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine C3H/HeJ</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kajikawa et al. 2010 [<xref rid="B43-vaccines-07-00150" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal sIgA when Co-Delivered with SE</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-1&#946;</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. acidophilus</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV-1 (Membrane Subunit Epitope)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG, Intestinal and Vaginal sIgA</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kajikawa et al. 2015 [<xref rid="B44-vaccines-07-00150" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Intestinal and Vaginal Epitope-Specific IgA B cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-4</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>IL-2</bold>
</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IL-2</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">L. rhamnosus</italic> GG</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Green Florescent Protein (GFP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Trafficking to MLN and Spleen.</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MurineC57BL/6 and BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kandasamy et al. 2011 [<xref rid="B45-vaccines-07-00150" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased MLN T Cells, IgA B Cells, DCs</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased GFP-Specific IgG and Fecal sIgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IFN-&#945;, IL-12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secreted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avian Influenza (Haemagglutinin 5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Serum IgA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Szatraj et al. 2014 [<xref rid="B46-vaccines-07-00150" ref-type="bibr">46</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>BAL: Bronchoalveolar lavage; GAL: Gastrointestinal lavage; MLN: Mesenteric lymph node.</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-07-00150-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-07-00150-t002_Table 2</object-id><label>Table 2</label><caption><p>Dendritic cell (DC) adjuvant strategies for lactic acid bacteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LAB</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th></tr></thead><tbody><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>DC-peptide</bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. acidophilus</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Bacillus anthracis</italic><break/>(Protective Antigen)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-12, IL-10, TNF&#945;, MCP-1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine A/J</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mohamadzadeh et al. 2009 [<xref rid="B67-vaccines-07-00150" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival to Challenge</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. gasseri</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Bacillus anthracis</italic><break/>(Protective Antigen)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine A/J</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mohamadzadeh et al. 2010 [<xref rid="B68-vaccines-07-00150" ref-type="bibr">68</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL6, MCP-1, IFN-&#947;, IL-12</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival to Challenge</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased T Cell Stimulation Following Challenge</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Newcastle Disease Virus<break/>(Hemagglutinin-Neuraminidase)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Intestinal sIgA</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chicken</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Jiang et al. 2015 [<xref rid="B69-vaccines-07-00150" ref-type="bibr">69</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic and Peripheral Blood CD4<sup>+</sup> T Cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival to Challenge</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Avian Influenza (Hemagglutinin)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c Chicken</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Shi et al. 2016 [<xref rid="B70-vaccines-07-00150" ref-type="bibr">70</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased MLN and PP DC Activation (CD80<sup>+</sup>, CD86<sup>+</sup>)<break/>Increased IFN-&#947;<break/>Increased Survival to Challenge with Decreased Lung Viral Titer</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased CD3<sup>+</sup> T Cell Proliferation and Increased CD3<sup>+</sup>CD4<sup>+</sup>/8<sup>+</sup> PBMC Percentages Increased IFN-&#947;<break/>Increased BAL sIgA and Serum IgG<break/>Decreased Lung Viral Titer</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Avian influenza (Nucleoprotein and Matrix Protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased PP and LP DC Activation (CD80<sup>+</sup>, CD86<sup>+</sup>, CD40<sup>+</sup>, MHCII<sup>+</sup>)</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c, C57BL/6</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yang et al. 2016 [<xref rid="B71-vaccines-07-00150" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased PP IgA<sup>+</sup> B Cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Fecal and BAL sIgA Titer</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, TNF-&#945;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased T Cell Proliferation</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival Rate to Challenge and Decreased Lesions and Virus in Lung</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine Epidemic Diarrhea Virus (Core Neutralizing Epitope)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased MLN and PP DC Activation (CD80<sup>+</sup>, CD86<sup>+</sup>, MHCII<sup>+</sup>)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wang et al. 2017 [<xref rid="B72-vaccines-07-00150" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG, Viral Neutralization, and Genital Tract and Intestinal Mucus sIgA Titer</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Lymphocyte Proliferation</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IL-4</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Enterotoxigenic <italic toggle="yes">E. coli</italic> (ETEC) (FaeG of K88 Fimbriae)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Adhesion to Porcine Intestinal Cells and Decreased Attachment of ETEC (In Vitro)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yang et al. 2017 [<xref rid="B73-vaccines-07-00150" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal sIgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic and MLN B Cells and DCs</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased TNF-&#945;, IL-12, IL-4<break/>Decreased Intestinal Lesions and Weight Loss Following Challenge</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Avian Influenza (Nucleoprotein and Matrix Protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral Intranasal</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chicken</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yang et al. 2017 [<xref rid="B61-vaccines-07-00150" ref-type="bibr">61</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic CD4<sup>+</sup> and CD8<sup>+</sup><break/>T Cells and T Cell Proliferation</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and BAL sIgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased Disease and Lung Virus Intranasal</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic CD8<sup>+</sup> T Cells and T Cell Proliferation <break/>Increased BAL sIgA </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased Disease and Lung Virus</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Eimeria tenella</italic> (SO7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal sIgA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chicken</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yang et al. 2017 [<xref rid="B74-vaccines-07-00150" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased Oocyst Shedding and Cecum Lesion Scores Following Challenge</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC-pep</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. acidophilus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surface-Display</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Clostridium botulinum</italic> (Botulinum Toxin Serotype A) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approximately 70% Protection to Challenge (Protection B cell-Mediated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sahay et al. 2018 [<xref rid="B75-vaccines-07-00150" ref-type="bibr">75</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine Epidemic Diarrhea Virus (Collagenase-Digested Fragment of S Protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal sIgA</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hou et al. 2018 [<xref rid="B62-vaccines-07-00150" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Th1/Th2 (IFN-&#947;/IL-4) CD4<sup>+</sup> T Cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased MLN TLR4, TLR9, and TGF-&#946; and Decreased TNF-&#945; Expression After Challenge</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival and Decreased Viral RNA After Challenge</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine Epidemic Diarrhea Virus (S Protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased DC Activation (CD40/CD80<sup>+</sup>)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Huang et al. 2018 [<xref rid="B76-vaccines-07-00150" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased PP IgA<sup>+</sup> B Cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Serum IgG, Intestinal sIgA, and Neutralizing Antibodies (IgG/sIgA)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased MLN IFN-&#947; and IL-17</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep and M cell targeting peptide (Col) </td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine Epidemic Diarrhea Virus (Core Neutralizing Epitope)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Vaginal, Intestinal Mucus, and Fecal sIgA</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ma et al. 2018 [<xref rid="B77-vaccines-07-00150" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic Lymphocyte Proliferation</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IL-4</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Antibody-Mediated Virus Neutralization</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DC-pep</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bovine Viral Diarrhea Virus Glycoprotein E2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased PP DC Activation (CD40<sup>+</sup>)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wang et at. 2019 [<xref rid="B78-vaccines-07-00150" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal sIgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Neutralizing IgG and sIgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IL-4</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic CD4<sup>+</sup>/CD8<sup>+</sup> T Cells and T Cell Stimulation</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Other</bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Complement (C3d3)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Human Chorionic Gonadotropin (hCG)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Serum/Vaginal IgG and IgA with Increased Longevity of Response</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vaginal</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c and C57BL/6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yao et al. 2007 [<xref rid="B63-vaccines-07-00150" ref-type="bibr">63</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased T and B Cell Proliferation</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Anti-CD205</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA (Plasmid)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased LAB DC Internalization</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Michon et al. 2015 [<xref rid="B64-vaccines-07-00150" ref-type="bibr">64</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Delivery of Plasmid to DCs</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Neonatal Fc receptor (FcRn)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza (Ectodomain of Matrix 2 Protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased DC Activation (CD86<sup>+</sup>/CD80<sup>+</sup>)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yang et al. 2017 [<xref rid="B65-vaccines-07-00150" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic and MLN IFN-&#947;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Intestinal sIgA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased MLN and PP IgA<sup>+</sup> B cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival and Decreased Viral Load Following Challenge</td></tr></tbody></table><table-wrap-foot><fn><p>BAL: Bronchoalveolar lavage; PP: Peyer&#8217;s patch; MLN: Mesenteric lymph node; DC: Dendritic cell; LP: Lamina propria.</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-07-00150-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-07-00150-t003_Table 3</object-id><label>Table 3</label><caption><p>Bacterial toxin adjuvant strategies for lactic acid bacteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LAB</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th></tr></thead><tbody><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Cholera Toxin (CT)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT subunit B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Co-administered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bordetella pertussis</italic> (Filamentous Haemagglutinin Adhesin)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colombi et al. 2006 [<xref rid="B90-vaccines-07-00150" ref-type="bibr">90</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CT subunit B</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Co-administered</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Avian Influenza (Hemagglutinin Antigen)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal sIgA</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lei et al. 2011 [<xref rid="B84-vaccines-07-00150" ref-type="bibr">84</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival to Challenge</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT subunit B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secreted </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Okuno et al. 2013 [<xref rid="B91-vaccines-07-00150" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CT subunit A1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza (Matrix Protein 2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and BAL sIgA</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral Intranasal</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chowdhury et al. 2014 [<xref rid="B85-vaccines-07-00150" ref-type="bibr">85</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947; (Intranasal)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Protection and Decreased Lung Viral Titer Following Challenge</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CT subunit A1</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza<break/>(Matrix Protein 2 and Hemagglutinin)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and BAL and Intestinal sIgA</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral Intranasal</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Li et al. 2015 [<xref rid="B86-vaccines-07-00150" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947; (Intranasal and Oral) and IL-4 (Intranasal)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased protection and decreased lung viral titer Following challenge</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longer Lasting Immune Response</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic toggle="yes">E. coli</italic> Heat-Liable Toxin (LT)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LT subunit B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surface-Display</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcine rotavirus (VP4 capsid protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Ocular, Vaginal, and Intestinal sIgA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qiao et al. 2009 [<xref rid="B92-vaccines-07-00150" ref-type="bibr">92</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LT subunit B</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display Secreted</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine Epidemic Diarrhea Virus (Core Neutralizing Epitope)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Intestinal, Vaginal, Nasal, Ocular, and Serum sIgA/IgA (Secreted Induced Highest Levels)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ge et al. 2012 [<xref rid="B87-vaccines-07-00150" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Neutralizing Antibodies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947; and IL-4</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LT subunit B and A (LTAK63)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-display</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Enterotoxigenic <italic toggle="yes">E. coli</italic> (F4 (K88) fimbrial adhesion FaeG)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal, Vaginal, and Nasal sIgA</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yu et al. 2016 [<xref rid="B93-vaccines-07-00150" ref-type="bibr">93</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic Lymphocyte Proliferation</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Protection to Challenge</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LT subunit B</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Avian influenza (hemagglutinin antigen)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Intestinal sIgA</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Jiang et al. 2017 [<xref rid="B88-vaccines-07-00150" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased CD4<sup>+</sup> T Cell IFN-&#947; (MLN), IL-4 (MLN, Splenic), IL-17 (MLN, Splenic) and CD8<sup>+</sup> T Cell IFN-&#947; (MLN, Splenic)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased PP IgA<sup>+</sup> B Cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Protection to Challenge</td></tr></tbody></table><table-wrap-foot><fn><p>BAL: Bronchoalveolar lavage; MLN: Mesenteric lymph node; PP: Peyer&#8217;s patch.</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-07-00150-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-07-00150-t004_Table 4</object-id><label>Table 4</label><caption><p>Bacterial derived adjuvant strategies for lactic acid bacteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LAB</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th></tr></thead><tbody><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Toll-like receptor 5 ligand</bold>
</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Salmonella flagellin</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Salmonella enterica</italic> (SipC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine C3H/HeJ</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kajikawa et al. 2010 [<xref rid="B94-vaccines-07-00150" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-2, GM-CSF, IFN-&#947;</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Salmonella flagellin</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. gasseri</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">None</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased TLR5 Stimulation</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Stoeker et al. 2011 [<xref rid="B95-vaccines-07-00150" ref-type="bibr">95</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased DC Maturation (MHCII<sup>+</sup>CD80<sup>+</sup>CD86<sup>-</sup>)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL17<sup>+</sup> Lymphocytes</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Lamina Propria Plasma Cells</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Salmonella flagellin </td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. acidophilus</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV-1 (Gag)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-1&#946;, IL-6</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kajikawa et al. 2012 [<xref rid="B96-vaccines-07-00150" ref-type="bibr">96</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgA-Secreting B Cells in FRT and LI</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased IFN-&#947; after HIV-1 In Vitro Exposure</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Enterocyte targeting</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Listeria monocytogenes</italic> Internalin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surface-Display</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA (GFP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Entry into Epithelial Cells and Delivery of GFP Plasmid </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guinea pigs Hartley</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guimaraes et al. 2005 [<xref rid="B97-vaccines-07-00150" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Internalin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surface-Display</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA (&#946;-Lactoglobulin Antigen)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased &#946;-Lactoglobulin in Intestinal Lumen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">de Azevedo et al. 2012 [<xref rid="B98-vaccines-07-00150" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fibronectic-Binding Protein A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surface-Display</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA (&#946;-Lactoglobulin Antigen)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased &#946;-Lactoglobulin in Intestinal Lumen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pontes et al. 2012 [<xref rid="B99-vaccines-07-00150" ref-type="bibr">99</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Fibronectic-Binding Protein A and Internalin A</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA (&#946;-Lactoglobulin Antigen)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral Intranasal</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pontes et al. 2014 [<xref rid="B100-vaccines-07-00150" ref-type="bibr">100</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-4, IL-5, Decreased IFN-&#947;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-5, Decreased IFN-&#947;</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Fibronectic-Binding Protein A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA (<italic toggle="yes">Mycobacterium tuberculosis</italic> Ag85A)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, TNF-&#945;, IL-6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intranasal</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine C57BL/6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mancha-Agresti et al. 2017 [<xref rid="B101-vaccines-07-00150" ref-type="bibr">101</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Serum IgG, IgA, and BAL IgG</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Additional bacterial derived adjuvants</bold>
</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Muramyl Dipeptide and Tuftsin</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted </td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Transmissible Gastroenteritis Virus (D Antigenic Site of the Spike Protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Intestinal, Serum, Nasal, Ocular, and Vaginal sIgA</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Jiang et al. 2014 [<xref rid="B102-vaccines-07-00150" ref-type="bibr">102</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Splenic T Cell Proliferation</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Antibody-Mediated Viral Neutralization</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IL-10, TGF-&#946;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Th17 Cells and Decreased Treg Cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Neisseria meningitidis</italic> PorA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytoplasmic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Helicobacter pylori (HpaA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vasquez et al. 2015 [<xref rid="B103-vaccines-07-00150" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytoplasmic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Trypanosoma cruzi</italic> (Trans-Sialidase Enzyme)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Immune Response to <italic toggle="yes">T. cruzi</italic> Challenge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quintana et al. 2018 [<xref rid="B104-vaccines-07-00150" ref-type="bibr">104</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Salmonella Resistance to Complement Killing</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-display</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Infectious Bursal Disease (VP2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Survival and Decreased Bursal Atrophy, Following Challenge (Intramuscular &gt; Oral)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral Intramuscular</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chicken</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wang et al. 2019 [<xref rid="B105-vaccines-07-00150" ref-type="bibr">105</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Neutralizing Antibody (Intramuscular &gt; Oral)</td></tr></tbody></table><table-wrap-foot><fn><p>DC: Dendritic cell; FRT: Female reproductive tract; LI: Large intestine; BAL: Bronchoalveolar lavage; TLR: Toll-like receptor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-07-00150-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-07-00150-t005_Table 5</object-id><label>Table 5</label><caption><p>Other adjuvant strategies for lactic acid bacteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LAB</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Herbal Medicine (JTT, HET)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Co-administered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human Papilloma Virus (E7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IL-2 Secretion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine C57/BL6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tagucki et al. 2012 [<xref rid="B116-vaccines-07-00150" ref-type="bibr">116</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">RANKL</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. lactis</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Secreted</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Brachyspira hyodysenteriae</italic> (Membrane Protein B)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased M Cell Development</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Murine BALB/c</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kim et al. 2015 [<xref rid="B117-vaccines-07-00150" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Fecal sIgA</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Thymosin &#945;-1</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">L. plantarum</italic>
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Surface-Display</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Classical Swine Fever (E2 Protein)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and Intestinal sIgA</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Xu et al. 2015 [<xref rid="B118-vaccines-07-00150" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Virus Neutralizing Antibodies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Cytotoxic Cells</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IFN-&#947;, IL-2, TNF-&#945;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased Protection to Challenge</td></tr></tbody></table><table-wrap-foot><fn><p>RANKL: Receptor activator of nuclear factor kappa-B ligand; M cell: Microfold cell.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>